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MUC1 is a large glycoprotein that is expressed on ductal epithelial cells and also the majority of 
epithelial adenocarcinomas.  Dysregulated expression of aberrantly glycoslyated MUC1 in 
carcinomas allows tumor-specific recognition of MUC1-derived epitopes by antibodies and T 
lymphocytes.  However, despite the ability of CTL to specifically recognize and kill MUC1+ 
tumor cells, immune responses in cancer patients fail to prevent tumor progression.  The failure 
of patients’ immune systems to eradicate MUC1+ tumors has been linked with their inability to 
mount MUC1-specific helper T cell responses. 
Here we show that CD4+ T cells play a central role in both the enhancement and suppression of 
MUC1-specific immune responses.  Using MUC1-Tg mice as a model for tolerance to self-
expressed MUC1, we show that MUC1-specific regulatory T cells (Tregs) respond to stimulation 
with MUC1 in the absence of a CD4+ T helper response.  The Treg:Th imbalance in MUC1-Tg 
mice causes the suppression of MUC1-specific immunity.  This suppression can be overcome by 
providing functional Th cells from WT mice.  To focus our studies on MUC1-specific CD4+ T 
cells, we created a TCR-transgenic mouse whose CD4+ T cells are specific for an MHC Class II-
restricted epitope derived from unglycosylated MUC1.  Using these mice, we have confirmed 
that adoptive transfer of MUC1-specific CD4+ T replaces the MUC1-specific T cell help that is 
missing in MUC1-Tg mice and restores their ability to respond to MUC1 vaccines.  This work 
shows that the generation of CD4 helper T cell responses is critical to establishing effective 
immunity to MUC1+ cancers. 
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PREFACE 
 
This is the section where one is expected to write something really profound.  However, 
that is not my style.  This dissertation is not about me, or about the countless times I worked 
through the night, only to obtain negative results.  Neither is this intended to be seen as a self-
important attempt at over-stating the importance of my work.  This is simply an account of a 
series of experiments that were designed to shed light on one small, yet fundamental part of the 
incredibly complex puzzle that is tumor immunology.  I hope that it makes interesting reading, or 
at the very least, a useful door-stop. 
 
I will simply leave you with the following quote from the book “Masquerade” by Terry 
Pratchett, which describes perfectly my experience as a graduate student… 
 
 
“…no matter how hard a thing is to do, once it has been done it’ll become a whole lot 
easier and will therefore be done a lot.  A huge mountain might be scaled by strong men only 
after many centuries of failed attempts, but a few decades later Grandmothers will be strolling up 
it for tea and then wandering back afterwards to see where they left their glasses.” 
 
 x
 STATEMENT OF PROBLEM 
 
Cancer is the second leading cause of death after heart disease.  Of all cancers, those of epithelial 
origin (lung, colon, pancreas etc) occupy the top five positions in terms of mortality (1).  The 
failure of conventional therapies to combat these diseases, in particular, pancreatic cancer has 
fuelled the search for novel forms of treatment. 
 
The discovery that tumor-associated antigens can be recognized by antibodies and T 
lymphocytes (2-4) strengthens the case that tumor-specific immune responses have the capacity 
to protect against various forms of cancer.  One such tumor-associated antigen is the epithelial 
cell mucin, MUC1, a large glycoprotein that is expressed on ductal epithelia and also on a wide 
range of epithelial carcinomas (5).  Cancer-associated changes in post-translational processing 
and expression of MUC1 allow MUC1-specific T cells to target MUC1+ tumors without harming 
the surrounding normal tissues.  This makes MUC1 it an attractive target for the immunological 
treatment of most adenocarcinomas (6).   
 
MUC1-specific immune responses can be detected in cancer patients (7-9).  However, they are 
unable to prevent tumor progression.  It is thought that MUC1-specific immune responses are 
weakened in cancer patients by the absence of MUC1-specific “T cell help”, which is provided 
by CD4+ “helper” T lymphocytes (Th cells).   
 
The following pages contain a description of a series of experiments that utilized a well-defined 
set of reagents, including a novel TCR transgenic mouse, to determine the role that MUC1-
specific CD4+ T cells play in modulating the immune response to MUC1. 
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1. INTRODUCTION 
 
1.1. Cancer and the Immune System 
In 1909, Paul Ehrlich first conceived the idea that the immune system might have the capacity to 
protect individuals from developing carcinomas (10).  However, it was not until 1957 that 
Thomas and Burnet formally proposed the hypothesis of cancer immunosurveillance (11-13).  
This hypothesis implicates the immune system as a sort of watch-dog, lying in wait for cells to 
turn cancerous, and states that: 
 
 “…small accumulations of tumour cells may develop and because of their possession 
of new antigenic potentialities provoke an effective immunological reaction with 
regression of the tumour and no clinical hint of its existence.” 
 
Considerable evidence now exists to indicate that this is, indeed, the case.  However, the immune 
surveillance system is not perfect; eventually a cancer cell arises that is able to evade the immune 
system long enough to grow into a detectable tumor mass.  A battle then ensues between the 
cancer cells and the immune system that is trying to suppress their growth.  If the cancer cells 
proliferate faster than they are being killed, the tumor will grow in size.  Conversely, an effective 
anti-tumor immune response will kill the cancer cells faster than they can multiply, in which case 
the tumor will shrink or “regress”.  The outcome depends on many factors: on the immune 
system side, genetics, age of the individual, and previous immune history determine the ability to 
respond efficiently; on the tumor side, specific mutations leading to loss of antigenicity and 
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 acquisition of the ability to produce immunosuppressive factors, determine the susceptibility to 
immune control.  
 
In the half-century since Burnet’s seminal paper, immunologists have worked to understand the 
mechanisms behind the anti-tumor immune response (14) in an attempt to harness its potential to 
provide effective protection against a wide array of different malignancies (2,15-18).  In order to 
fully understand how the immune system responds to tumors, it is important to understand the 
interaction of the major cell types that are involved in the anti-tumor immune response. 
 
1.2. Induction of Tumor Immunity 
 
1.2.1. Dendritic Cells Present Tumor Antigens to T cells 
DC are the most potent antigen-presenting cells (APC) and the only ones with the ability to 
prime naïve T cells (i.e. T cells that never encountered their specific antigen) and are therefore 
the initiators of the adaptive immune response (19).  Dendritic Cells act as the sentinels of the 
immune system.  They develop in the bone marrow and then travel to other tissues, where they 
take up temporary residence, sampling the environment within the peripheral tissues by ingesting 
particulate matter, such as bacteria, viruses, or pieces of tumor cells (20).  Having sampled the 
tissues, DC travel to the draining lymph node, where they ‘present’ peptides derived from 
“processed” antigens to antigen-specific T cells.  T cells express a receptor on their surface 
called the “T cell antigen receptor” (TCR) (described in detail later), which allows them to 
recognize antigenic peptides bound to MHC Class I or Class II molecules on the DC cell surface.  
3 
 Although each MHC molecule can bind to only one peptide at a time, a single DC has thousands 
of MHC molecules, so it can simultaneously present many different peptides on its surface.   
 
1.2.2. DC control the decision between immunity and toleranace 
Ligation of the TCR by its cognate peptide:MHC complex provides the first of two signals that 
are required by the T cell for its full stimulation.  The second signal can come in many different 
guises, collectively termed “co-stimulation”.  Examples of co-stimulatory molecules expressed 
by DC are CD40, CD80, CD86, ICOS and OX40L (21-23).  Originally, the presence of co-
stimulatory molecules on the DC was observed to be beneficial, even essential, for optimal T cell 
activation (21,24-26).  Recently however, it has been shown that co-stimulation also has 
inhibitory effects and may have a role in preventing autoimmunity by tolerizing self-reactive T 
cells (22,23,27,28). 
 
The context in which the DC acquires the peripheral antigens (i.e. in the presence or absence of 
an inflammatory response to an insult or injury) determines its activation status and the type of 
costimulation that it can provide to T cells when it arrives in the lymph node.  This will affect the 
outcome of its interaction with antigen-specific T cells.   
Dendritic Cells use numerous receptors to recognize conserved ligands on potential pathogens 
(e.g. recognition of bacterial CpG by TLR9) (29-31).  Upon detection of such pathogens, the DC 
become activated, upregulate co-stimulatory molecules, and begin to produce inflammatory 
cytokines such as IL-12, TNF-alpha (32,33).  DC activated in such a fashion are able to 
efficiently stimulate antigen-specific T cells in the lymph nodes, which will return to the site of 
the infection to eliminate any infected cells.  However, if the tissue is not under attack, the DC 
4 
 will arrive in the lymph node in a quiescent state (low level of costimulatory molecules, no 
cytokine production), presenting only ‘self’ tissue-antigens, and reporting that everything is 
normal.  T cells that recognize self-antigens on quiescent DC will only receive signal 1 and thus 
be tolerized (deleted or functionally altered) and prevented from traveling to the tissue and 
causing autoimmunity (34). 
 
The terms “mature DC” and “immature DC” have been used to describe the status of the DC in 
these two situations and can be defined by the presence or absence of certain molecules on the 
surface of the DC (e.g. CD40, CD80, CD86).  However, description of a DC as “mature” does 
not necessarily determine the outcome of its interaction with a naïve T cell; it has been shown 
that mature DC expressing high levels of co-stimulatory molecules can be either stimulatory or 
tolerogenic (23,35,36).  Other molecules, such as the cytokines IL-12 and IL-10, are thought to 
be involved in the decision between immunity and tolerance (35), although the details of this 
switch are not fully understood. 
The main point to be made is that DC can only instruct naïve T cells to become effector cells if 
they receive ‘danger’ signals induced by an active injury or infection (37) that result in 
upregulation of co-stimulatory molecules and production of inflammatory cytokines.  A benign 
tumor, developing slowly over a long period of time, is unlikely to cause the widespread tissue 
destruction necessary to elicit the danger signals required for activating DC (38).  Tumor 
immunologists wishing to elicit effective anti-tumor immunity are attempting to understand how 
it might be possible to dictate the context in which DC present tumor antigens, such that 
effective anti-tumor immunity can l be established. 
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 1.2.3. Tumor-specific CTL and helper T cells 
For many years, CD8+ T cells representing primarily cytotoxic T lymphocytes (CTL) received 
much attention as the cells that are primarily responsible for mediating immunological rejection 
of tumors.  Since adenocarcinomas express MHC Class I molecules and lack MHC Class II, 
CD8+ CTL that recognize MHC Class I peptide complexes are the cells which directly recognize 
tumor antigens on the surface of cancer cells (39,40) and initiate apoptotic death of tumor cells 
via release of lytic granules or by Fas-FasL interactions (41).  CD4+ T cells, on the other hand, 
recognize most tumor antigens cross-presented by DC in their MHC Class II molecules.  This 
indirect recognition of tumor antigens by CD4+ cells, until recently considered to be only helper 
cells, has led to questioning their precise role in anti-tumor immunity. 
 
Given a strong enough stimulus, such as highly activated DC and optimal concentrations of 
antigen, primary CD8 T cell responses to tumors can be generated in the absence of helper  T 
cells (42).   However, there is an apparent requirement for help from CD4+ T cells in the 
establishment of effective CTL memory (43).  Evidence from several models of acute infections 
suggests that CD4+ T cells are required for the priming (44,45) and maintenance (46) of memory 
CTL, although it is unclear whether they are also required for re-stimulation of memory CTL in 
the recall response (44,47).  These CD4+ helper T cells (Th) mediate their effect through the 
dendritic cell.  When Th cells recognize specific antigen presented on a properly activated DC, 
they provide signals via CD40L which ‘license’ the DC to provide the proper co-stimulation for 
antigen-specific CTL (24-26,48).  There is a significant body of evidence in support of a similar 
role for CD4+ T cells in the generation of productive tumor immunity (16,49-51).  Some of the 
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 most striking evidence is from observations that some tumors render CD4+ T cells non-
responsive in order to avoid rejection (52,53). 
 
 
CD4+ Regulatory T cells 1.2.4. 
A relatively recent addition to the T cell family is a sub-population of CD4+ T cells called 
regulatory T cells (Tregs).  These have the opposite function from helper T cells in that they 
suppress T and B cell responses.  Tregs are defined by expression of CD4, CD25 and FoxP3 
(54); GITR, CD62L and CD27 have been implicated as additional markers (55-57).  Tregs exert 
their suppression either by cell-cell contact, or by secretion of the cytokines IL-10 or TGF-
β(58,59).  Tregs are thymically derived and have an important role in the maintenance of 
tolerance to self-antigens (60-64), although they also control immune responses to pathogens 
(65,66).  The presence of Tregs in cancer patients correlates negatively with strength of the 
tumor-specific immune response and prognosis (67-69) and depletion of Tregs enhances the anti-
tumor immune response (70,71).  CD4+CD25+ Tregs were originally thought to be anergic, as 
they appeared to lack classical features of T cell activation such as proliferation and cytokine 
production (66,70).  However, recent studies have shown that their proliferation can be induced 
by different subsets of dendritic cells (35,60,72-75). 
 
The balance between immunity and tolerance is therefore an active process involving the 
interaction of DC and CD4+ T cells (20,43).  CD8 T cells seem to take more of a passive role; 
they are either stimulated by the DC, or they remain ignorant.  Therefore, DC and CD4+ T cells 
are the controllers of the adaptive immune response, whereas CD8 T cells simply follow their 
7 
 lead.  By dictating the nature of the Th-DC interaction, one might hope to influence the 
establishment of effective tumor-specific memory CTL responses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The next section was modified from Cancer Chemotherapy & Biologial Response Modifiers, Vol 21, pp 259 – 274, 
Michael S. Turner, John R. McKolanis, Ramesh K. Ramanathan, David C Whitcomb, Olivera J. Finn, “Mucins in 
gastrointestinal cancers”, Copyright (2004), with permission from Elsevier.  Copyright permission is kept on file 
with Michael Turner. 
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1.3. Mucin Expression in Gastrointestinal Cancers 
 
 
Gastrointestinal cancers originate from malignant transformation of normal epithelial cells that 
line the gastrointestinal tract and various other ductal structures.  The same cell type gives origin 
to other human solid tumors, such as breast cancer, non-small cell lung cancer, kidney cancer, 
bladder cancer, prostate cancer, etc.  Because of this, tumors that appear to be widely different, 
e.g. colon cancer and breast cancer, express in common numerous molecules that are 
characteristic of epithelial cells.   Among many such molecules, those belonging to the mucin 
family have been very extensively studied due to their special characteristics that can help define 
and diagnose various gastrointestinal pathologies, including cancer. 
 
1.3.1. The Mucin family of glycoproteins 
Mucins are large secreted and/or transmembrane glycoproteins, predominantly expressed on the 
luminal surfaces of wet epithelia (5).  The mucin family has steadily grown over the last 15 
years, numbering currently fourteen different members encoded by genes MUC1-MUC14.  Their 
pattern of expression varies depending on the histological site as well as the integrity of the site, 
and the gradient from normal to diseased state. The common feature that is shared by all mucins, 
which distinguishes them from mucin-like glycoproteins, is a large region composed of variable 
number of tandem repeats (VNTR).  The amino acid sequence and length of the tandem repeats 
is different for each mucin gene.   
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 1.3.2. Glycosylation of Mucins 
More than 50% of molecular weight of mucins is derived from O-linked carbohydrates attached 
to numerous serine and threonine residues found in the tandem repeats.  Addition of sialic acid to 
the terminal sugars gives these molecules their mucinous character (76-80). Early studies with 
monoclonal antibodies reactive with epithelial tumors revealed that some antibodies recognized 
only mucin epitopes uniquely expressed on malignant cells (9,81,82).  It is now understood that 
this is due to aberrant glycosylation of tumor mucins, which creates tumor specific glycoepitopes 
as well as tumor specific peptide epitopes (81,83-86).  Attachment of O-glycans to the mucin 
peptide backbone and subsequent elongation and branching of carbohydrate chains occurs in the 
Golgi apparatus and is initiated by polypeptidyl N-acetylgalactosaminyltransferases (GalNAc-
T’s), which transfer N-acetylgalactosamine (GalNAc) to the Ser/Thr residues.  Further 
monosaccharides, mainly galactose (Gal) and/or N-acetylglucosamine (GlcNAC), are then added 
to form long, branched carbohydrate chains.  Finally, α-anomeric monosaccharides, such as α-
fucose, α-sialic acids, α-Gal or α-GalNAc, are added to the periphery in different combinations 
to form blood-group carbohydrate antigens such as A, B, H and the Lewis group (87). Cancer 
cells exhibit changes in the composition and relative levels of glycosyltransferases that perform 
O-glycosylation of mucins.  Furthermore, an increase in sialyltransferases (88), which leads to 
premature addition of sialic acid, acts as a stop signal preventing further elongation and results in 
the truncation of the carbohydrate chains (89,90).  These cancer-associated changes result in 
qualitatively as well as quantitatively different mucin glycosylation, producing carbohydrates 
that are not found on normal cells and have been used as tumor markers.  The best examples are 
… T, …sT, …Tn and …sTn (91,92)..  Decreased glycosylation of the polypeptide core also 
exposes peptide epitopes on tumor mucins that are not exposed on normal mucins. 
10 
  
These new tumor specific mucin epitopes offer a unique opportunity to design mucin-based 
diagnostic as well as therapeutic approaches for managing human epithelial tumors, such as 
gastrointestinal tumors.  In the rest of the chapter we will provide examples of how cancer- 
associated changes in mucin expression have been used already in diagnosis and therapy of GI 
malignancies and foreshadow future uses of some of the most promising candidates for 
immunotherapy and prevention of GI cancers. 
      
1.3.3. Mucin Expression Patterns in healthy & diseased tissues 
Various members of the mucin family are expressed in different regions and on different cell-
types within the GI tract.  Furthermore, the expression patterns of individual mucins correlate 
with different stages of disease and with prognosis (Table 1).  Characterization of these 
expression patterns is now maturing to the point that it can provide methods for early detection 
of cancer-associated changes within the mucosa, which in turn will allow timely intervention.  
Below are examples of the best-studied preneoplastic and cancerous states that are characterized 
by specific patterns of mucin expression. 
 
1.3.3.1. Esophageal mucins 
Normal esophagus expresses low levels of MUC5B in the submucosal glands and MUC1 and 
MUC4 in the stratified squamous epithelium.  Two types of malignancies arise from these 
tissues, esophageal adenocarcinomas and esophageal squamous cell carcinomas. Barrett’s 
metaplasia (Barrett’s Esophagus) is a premalignant lesion of the esophagus that usually precedes 
Barrett’s adenocarcinoma.  For a long time, it was unclear whether Barrett’s Esophagus 
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 represented an intermediate stage of transformation towards full-blown carcinoma, or whether 
the two states occurred independently of each other.  In recent years, mucin gene expression has 
been used to show that the former is the case, by characterizing the steps involved in the 
transition from normal epithelial cells in the esophagus, through Barrett's Esophagus to 
esophageal adenocarcinoma (93,94).  Mucin patterns were also used to further differentiate 
esophageal adenocarcinomas from squamous cell carcinoma. Upregulation of MUC1 and MUC4 
in the absence of mucins 2, 3 and 5, is a diagnostic mucin signature of squamous cell 
carcinomas. Barrett’s adenocarcinomas, on the other hand, were found to upregulate mucins 2-6 
but not MUC1.  Interestingly, of the Barrett’s adenocarcinoma-associated mucins, MUC2, 
MUC3 and MUC4 correlated with intestinal metaplasia, whereas expression of MUC5AC and 
MUC6 was observed in gastric metaplasia (94).  From these studies, it appears that gastric and 
intestinal metaplasia of the esophagus are intermediate steps in the development of Barrett’s 
adenocarcinoma, but not esophageal squamous cell carcinoma. 
 
Expression of MUC1 and MUC2 has been correlated with malignant potential of esophageal 
dysplasia (95,96).  MUC1 is absent in dysplastic epithelium but upregulated in both Barrett’s 
adenocarcinoma (95) and squamous cell carcinomas (96), which makes it a good diagnostic 
marker for cancer.  MUC2 is also a good diagnostic marker because it is present in dysplastic 
lesions but completely absent in cancerous lesions.  While mucins that are diminished in 
expression or completely turned off in the progression from normal to dysplastic to cancerous 
state can be used to properly diagnose a biopsy, the mucins that are upregulated in cancer, such 
as MUC1, can also be used as targets for therapy. 
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 1.3.3.2. Gastric mucins 
As with the esophageal cancers, as well as most other carcinomas, there is a series of sequential 
steps in the development of gastric adenocarcinomas, starting with gastritis and passing 
sequentially through intestinal metaplasia, dysplasia, intramucosal carcinoma and finally 
invasive carcinoma (97-99).  In parallel with disease progression, there exists a spectrum of 
mucin expression, with certain mucins being associated with specific stages of disease and in 
some cases correlating also with clinical outcome.  In normal gastric mucosa, MUC1, MUC5AC 
and MUC6 are expressed in a cell type-specific manner, with MUC1 and MUC5AC found in 
superficial epithelium and MUC6 in the deep (antral) glands (100).  MUC2 is not found in 
normal gastric epithelium, although it is expressed by goblet cells during intestinal metaplasia.  
MUC1 expression increases during the gastric adenoma to carcinoma progression and correlates 
with poorer outcome in patients with gastric carcinomas (100).  Conversely, patients with 
MUC2+ tumors show better survival.  The other mucin genes do not show a reproducible or 
characteristic pattern of expression in gastric carcinomas, even though increase in heterogeneity 
of mucin gene expression is frequently seen and appears to correlate with advanced stages of 
gastric cancers (101). 
 
1.3.3.3. Pancreatic mucins 
Three main types of ductal pancreatic tumors have been characterized with respect to mucin gene 
expression:  (1) Invasive ductal adenocarcinoma, which is the most common, highly malignant 
and carries the worst prognosis; (2) Intraductal papillary mucinous neoplasia (IPMN), which are 
usually relatively benign; (3) Mucinous cystic neoplasia (MCN), which almost exclusively only 
affect women and, if noninvasive, can be treated simply by resection of the pancreatic tail. 
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 Pancreatic tumors have different mucin expression patterns and these correlate with 
aggressiveness of the tumors.  MCN express MUC5AC ubiquitously, and MUC2 in goblet cells.  
MUC1 is only expressed in areas of invasion (102).  IPMN are similar, in that MUC5AC is 
widely expressed, MUC2 is found only in the dark cell type, and MUC1 was observed in the 
compact cell type and in areas of dark cell type that showed carcinomatous change and 
invasiveness (103).  In pancreatic ductal adenocarcinoma, however, the pattern is quite different.  
Upregulation of MUC1 and MUC6 and de-novo expression of MUC5AC occurs early in 
pancreatic intra-epithelial neoplasia and is maintained in the majority of ductal adenocarcinomas.  
MUC2 is rarely expressed.  (104,105). 
 
The distinct patterns of mucin expression in these different forms of pancreatic cancer suggest 
different pathways of oncogenesis, which may require different forms of treatment.  However, 
there are some common characteristics from which some important conclusions can be drawn.  
In common with other gastro-intestinal epithelia, over-expression of MUC1 and loss of MUC2 in 
the pancreas correlates with invasiveness and poor prognosis.  Hence, pancreatic 
adenocarcinomas that have the combined phenotype of MUC1+ MUC2-, show worse patient 
survival rates than MCN or IPMN.  Because of the high level of expression of MUC1 in 
pancreatic adenocarcinomas, and many cancer-associated changes in MUC1 glycosylation, this 
mucin has been extensively explored as a target for immune attack on tumor cells, as well as an 
immunogen to elicit tumor-specific immune responses. 
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 1.3.3.4. Colonic mucins 
Normal colon is characterized by the expression of MUC2, MUC3 and MUC4, but that pattern 
changes in a very characteristic fashion during the progression from polyps to adenomas to 
adenocarcinomas.  While MUC1 is not expressed in normal colonic epithelium, it is found in the 
majority of adenomatous dysplasia and almost all colorectal adenocarcinomas (106,107).  
Conversely, loss of MUC2 expression is observed in over 50% of severely dysplastic adenomas 
and carcinomas.  This correlates with the Ki-67 proliferation index, suggesting a link between 
decreased MUC2 expression and malignant transformation (106).  A recent report showed 
conclusively that mice made genetically defective in the MUC2 gene, frequently develop 
intestinal adenocarcinomas and rectal tumors (108).  Thus, MUC1 and MUC2 expression can be 
correlated with disease progression, with MUC2 having an apparent role in the suppression of 
colorectal carcinomas. 
 
MUC4 is another mucin whose expression is lost in polyps and adenomas (109).  Evidence from 
other epithelial organs suggests a link between MUC4 and highly invasive carcinomas, although 
this correlation is not clear for intestinal epithelia. MUC5AC and MUC6 are both expressed 
mainly in the intermediate developmental stages of intestinal adenocarcinomas.  Neither one is 
expressed in the normal lower intestine, yet they are expressed at a high level in moderate 
dysplasia and at a lower level in carcinomas (110,111). 
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Table 1. Expression Patterns of gastro-intestinal mucins in normal and tumor tissues 
Site MUC1 MUC2 MUC3 MUC4 MUC5AC MUC5B MUC6 
Normal 
Esophagus +
a - - + - + - 
Esophageal  
Squamous 
Carcinoma 
++ +/- - ++ - - - 
Barrett’s 
Metaplasia - 
+ 
 Int f
+  
Int 
+  
Int 
+ 
  Gastric - 
+   
Gastric 
Barrett’s 
Adenocarcinoma +/- +/- + + + - + 
Normal Stomach + - - - + NDb + 
Gastric IMc +/- +   +/- ND +/- 
Gastric Cancer ++/- + + + - ND +/- 
Normal Pancreas + - +/- - - + + 
IPMNd - +/- ND ND + ND ND 
MCNe - 
+  
Goblet 
cells 
ND ND + ND - 
Pancreatic 
Adenocarcinoma ++ - ND + + ND ++ 
Normal Intestine - ++ ND ND - ND - 
Intestinal 
Adenoma + + ND ND ++ ND ++ 
Intestinal 
Carcinoma ++ +/- ND ND + ND + 
    
a Increase in the number of +’s indicates an increase in the level of expression. 
b ND, Not Determined 
c IM, Intestinal Metaplasia 
d IPMN, Intraductal Papillary Mucinous Neoplasia  
e MCN, Mucinous Cystic Neoplasia 
f Int, Intestinal 
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 1.4. Mucin-based Therapy 
The cancer-associated changes in mucin expression described above suggest that certain mucins 
may be used as targets for treatment and prevention of specific GI cancers.  For most of the 
mucins, however, there is not always a clear-cut difference of expression between normal and 
neoplastic tissues and thus targeting those molecules may not under most circumstances be 
tumor specific.  For example, even though MUC5AC is overexpressed in many gastrointestinal 
cancers, it is also expressed on the normal epithelium in many parts of the GI tract.  MUC2 is the 
most abundantly secreted intestinal mucin and is over-expressed in all mucinous tumors of colon, 
breast, ovary and pancreas (112,113).  However, in adenocarcinomas, MUC2 appears to act as a 
tumor suppressor and loss of its expression is associated with a more aggressive phenotype.  
Therapy-induced selection pressure against the expression of MUC2 could lead to the outgrowth 
of MUC2- tumors, which evidence suggests, would be even more aggressive than the original 
tumor.  Another factor to consider when designing mucin-based therapies is that most of these 
molecules are shed or secreted by tumor cells and may not be suitable targets for some therapies.  
Of the 14 mucins described so far, only MUC1, MUC4 and MUC5AC are transmembrane, cell-
associated molecules that could be used to target tumor cells with various forms of therapy.  
MUC1 is by far the best characterized for its tumor specific expression and antigenicity. 
 
1.4.1. Mucin-based immunotherapy 
There are compelling reasons to consider mucins as potential immunotherapy targets.  The major 
ones are the difference in gene expression between normal and abnormal tissues, described 
above, and the cancer-associated pattern of glycosylation that distinguishes cancer mucins from 
normal mucins.  By directing immune responses against the cancer-associated forms, one can 
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 expect to elicit protective or therapeutic immunity without causing collateral autoimmune 
damage. Cancer associated mucin forms can be targeted through passive immunotherapy with 
preformed immune effector mechanisms, such as antibodies or T cells that can be administered 
to the patient in hope of destroying tumor cells remaining after surgery or chemotherapy.  The 
other alternative is active specific immunotherapy where mucin molecules are used as 
immunogens in vaccines designed to elicit anti-mucin and therefore anti-tumor immunity. 
 
Antibody mediated therapy for cancer (114) has gained in popularity in recent years due to 
successes obtained with such therapy in breast cancer (115) and B cell lymphomas (116).  Even 
though one of the more successful antibody trials has been in colon cancer (117) using an 
antibody against a tumor glycoprotein similar to a transmembrane mucin, therapy with anti-
mucin antibodies has not been sufficiently explored in GI cancers.  As mentioned above most 
mucins are secreted molecules and thus have not been considered good targets for such therapy.  
This concern is justifiable in cases where the antibody is used to deliver drugs, toxins or 
radioisotopes to cancer cells.  However, antibodies may serve additional functions, one of which 
is the formation of immune complexes with soluble mucins that could be taken up by Fc 
receptors on dendritic cells.  This route of endocytosis favors processing and presentation of 
antigens in the class I pathway (118,119) and may help generate additional mucin specific CTL.  
At the very least, the cell-associated mucins should be considered as targets for immunotherapy 
of GI cancers.   An antibody against a cell membrane associated mucin MUC1 did show positive 
result when used to treat ovarian cancer (120) and there are reasons to believe that other tumors 
that overexpress tumor forms of MUC1 should be candidates for therapy with that antibody.  It is 
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 hoped that newly aroused interest in antibody therapy in general will provoke greater efforts in 
testing anti-mucin antibodies in therapy of GI cancers. 
 
1.4.2. 
1.4.3. 
Immune responses to MUC1 
Of all the gastrointestinal mucins, MUC1 has the strongest association with 
aggressiveness/malignancy and prognosis (121).  MUC1 is normally highly glycosylated and its 
normal expression is at very low levels and restricted to the apical surface of ductal epithelia.  
Thus, the potentially antigenic peptide core of native MUC1 is anatomically and sterically 
inaccessible to the immune system, especially the antibodies.  During the process of 
carcinogenesis, normal epithelial cell polarity is lost, such that on tumor cells there is no clear 
distinction between the basolateral and apical surfaces.  This results in expression of MUC1 over 
the entire tumor cell surface (121) where it is for the first time accessible to the cells of the 
immune system and specific antibodies.  Furthermore, cancer-associated truncation of O-linked 
carbohydrate chains creates tumor-specific and immunogenic T and Tn antigens (87,122,123) on 
the protein core of the tandem repeats, which can also be sialylated (sT and sTN), thereby 
creating at least four tumor antigens that  can be recognized by antibodies (91,123).  Tumor-
specific T cells can also distinguish cancer-associated peptide and glycopeptide epitopes from 
normally glycosylated MUC1 epitopes (8,9,124). 
 
 
Anti-MUC1 immunity induced by tumor growth 
Many studies have shown that patients suffering from tumors that overexpress MUC1 possess 
antibodies and T cells that recognize tumor forms of MUC1.  However, these humoral and 
cellular immune responses that are induced during tumor development are very weak, with 
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 antibody titers and T cell frequency being considerably below what would be expected to be a 
therapeutic level.  Nevertheless, in some instances the presence of antibodies against MUC1 can 
be correlated with favorable disease outcome (i.e. patients with MUC1-specific antibodies did 
not experience recurrent tumors) (125).  Although the presence of MUC1-specific antibodies is 
indicative of an immune response, antibodies alone have little effect, if any, on the growth of 
solid tumors (126).  It is also striking that MUC1-specific antibodies that are induced in response 
to the tumor, are predominantly of the IgM type (127).  This indicates that MUC1-specific B 
cells do not receive the help from antigen-specific CD4+ T cells necessary to allow them to 
switch to the production of other immunoglobulin isotypes.   
 
MUC1-specific T cells are also induced in patients during the growth of MUC1 expressing 
tumors.  The first to be described were derived from lymph nodes of pancreatic, breast and colon 
cancer patients and shown to recognize underglycosylated MUC1 on tumors in an MHC-
unrestricted manner (8).  These MHC-unrestricted CTL proliferate in response to tumor-derived 
MUC1 in the absence of antigen presenting cells, and they can lyse MUC1+ target tumor cells, 
regardless of the HLA alleles that they express. Structural analyses of un-glycosylated MUC1 
offered an explanation for its distinctive antigenic properties related to the ability to activate 
specific T cells.  Every 20 amino acid-long tandem repeat on the MUC1 polypeptide core 
contains five proline residues, which give a rigid rod-like structure to the protein.  Protruding 
from each tandem repeat is a beta-turn helical knob, which corresponds to the PDTRP sequence 
(128).  It is this sequence that is recognized by antibodies and T cells from cancer patients 
(9,129,130).  This particular epitope, as well as potentially others, are located on the tandem 
repeat structure that imparts an antigenic multivalency, such that each mucin molecule may be 
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 bound by many T cell receptors on a single T cell.  It has been shown that more than two repeats 
are required to activate T cells in an MHC un-restricted fashion. MUC1 engineered to have only 
two repeats must be expressed at very high levels on the target cell surface to elicit a T cell 
response (131).  Binding of many T cell receptors along the length of one MUC1 molecule 
allows them to be cross-linked sufficiently to induce the intracellular signals required for T cell 
activation (132).  
 
CTL can also recognize MUC1 in the context of MHC class I molecules.  Peptide binding 
studies were performed with 8, 9 and 10 amino acid long peptides derived from the MUC1 
tandem repeat sequence to investigate their ability to bind to various human HLA-class I 
molecules and be presented to T cells.  Peptide STAPPAHGV was found to bind to HLA-A1, -
A2.1, -A3, and -A11 (133).  T cells from healthy A-11+ donors were stimulated when this 
peptide was presented by HLA-A11 and a secondary response to this peptide was observed in 
LN cells from an HLA-A11+ cancer patient.  A subsequent study showed that a longer MUC1 
peptide containing five tandem repeats primed a broader CTL repertoire that was restricted by 
HLA-A1 (134).  Studies in mice expressing a transgene for HLA-A2 have shown that 
immunization with MUC1-derived peptides produces CTL that lyse human A2+ PBMC’s loaded 
with the same peptide (135).  This evidence that tumor growth can elicit antibodies and MHC-
restricted and un-restricted CTL responses, albeit to very low, non-therapeutic levels, proves the 
immunogenicity of tumor MUC1 and supports current efforts to design vaccines that will 
specifically amplify those immune responses. 
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 Given the central role that T cell help plays in coordinating and enhancing immune responses, 
the absence of a MUC1-specific CD4+ T cell response in cancer patients may be the major 
obstacle in the generation of effective, long-term immunity to MUC1.  If we can understand the 
reasons for inefficient helper T cell stimulation, it will be possible to correct this problem 
through therapy directed towards providing MUC1-specific helper T cells.  They could be 
generated in vitro by priming on DC that have processed MUC1 antigen, expanded to large 
numbers and adoptively transferred into the patient.  The presence of helper T cells may boost 
proliferation of existing CTL as well as help B cells switch from making only MUC1-specific 
IgM, to other Ig isotypes.  Alternatively, patients who have not been extensively treated and are 
not immunosuppressed might be vaccinated with MUC1 forms that can be processed in vivo and 
presented to helper T cells.  The preclinical studies in mice described here aim to test these 
approaches. 
 
 
1.4.4. Preclinical models of MUC1 immunotherapy in MUC1-Tg mice 
Studies in mice have shown that both CD4+ and CD8+ T lymphocytes can respond specifically to 
tumors that express MUC1 (6).  However, the amino acid sequence of murine Muc1 shares very 
little similarity with that of human MUC1 (convention is that murine Muc1 is written in lower 
case, whereas human MUC1 is written in upper case).  Therefore, the robust cellular and 
humoral responses to human MUC1 seen in WT mice are immune responses to a ‘foreign’ 
antigen and may not accurately represent responses that could be expected in patients where 
MUC1 for the most part is a self-molecule.  The need for a model which better mimics the 
situation in humans prompted the creation of MUC1-transgenic (MUC1-Tg) mice (136,137), in 
which human MUC1 is expressed as a self-antigen and is regulated by its endogenous promoter.  
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 These mice express and glycosylate MUC1 with the same cell-type and tissue-type specificity as 
humans (138). They have been studied for their ability to mount anti-MUC1 immune responses 
following vaccination, as well as bred with mice engineered to develop various tumors, in order 
to study MUC1 responses during tumor growth and tumor rejection.  For example, a mouse 
model of MUC1 pancreatic cancer was developed by crossing MUC1 transgenic mice with 
transgenic mice that express the first 127 aa of the SV40 large T antigen under the control of 
elastase promoter (ET).  50% of the mice develop tumors at 12 weeks of age and clinical signs of 
disease at 21 weeks of age (139). The double transgenic mice (MET) develop pancreatic tumors 
that express human MUC1 (138). The mice exhibit dysplasia at birth that progress to 
microadenomas and then to full-blown adenocarcinomas.  The tumors express high levels of 
underglycosylated MUC1, like human tumors, and that is accompanied by circulating MUC1 in 
the serum and presence of low titers of anti-MUC1 IgM (as in cancer patients).   
 
Unlike wild-type (WT) mice, MUC1-Tg mice fail to initiate IgG class switching or mount CD4+ 
T cell responses to MUC1+ tumors (50,51) in response to many standard immunization 
protocols.  In that way also, they mimic the human situation and have been used by several 
groups as a pre-clinical model to evaluate different vaccine strategies as methods of inducing a 
protective immunity to MUC1+ tumors.  Immunization with dendritic cells fused to MUC1+ 
tumor cells induces MUC1-specific humoral and cellular immunity capable of rejecting 
experimental pulmonary metastases of the same cell line (140).  Effector CTL isolated from 
these mice lysed the MUC1+ tumor cells in vitro.  In addition LN cells from immunized mice 
responded in vitro to exogenous MUC1, and the response was dependent on CD4, MHC-class II 
and costimulatory molecules B7.1, B7.2 and CD40L (141).  These results suggested that fusion 
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 of DC with tumor cells provided the MHC class II presentation of MUC1 as well as 
costimulation required to activate MUC1-specific CD4+ T cells, which in turn enhanced the CTL 
response to mediate rejection of MUC1+ metastatic foci.   
 
Inasmuch as the goal is to induce MUC1-specific immunity against MUC1+ tumors, dendritic 
cell-based vaccines that utilize defined MUC1 protein or peptides instead of whole tumor cells or 
tumor cell lysates, offer a safer and better controlled alternative.  However, MUC1-Tg mice 
immunized sub-cutaneously with MUC1 peptide-loaded DC mount mediocre CTL responses and 
virtually undetectable CD4+ T cell responses (50).  The goal of the studies described here is to 
determine why these CD4+ T cell responses are so weak, and whether improving them will result 
in improved immunity to MUC1+ tumors. 
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 1.5. The T Cell antigen Receptor 
 
Chapter 3 describes the generation of a novel transgenic mouse, VFT, and its use in the 
elucidatation of the response of MUC1-specific CD4+ T cells to MUC1.  In order to understand 
the procedure used in the identification and cloning of the MUC1-specific TCR expressed in this 
mouse, one must be familiar with the basic components of the TCR and how they combine 
differently in each T cell to form a unique receptor that confers antigen specificity upon that T 
cell. 
 
 
 
1.5.1. Structure of the TCR 
Each T cell carries a unique TCR on its surface and each TCR is specific for a different antigen.  
Despite this massive variation in the TCR repertoire, there are certain structural features that are 
common to every TCR.  All TCRs are transmembrane heterodimers, consisting of a TCRα chain 
and a TCRβ chain.  Each TCR chain is sub-divided into smaller regions, V (variable), J (joining), 
D (diversity; TCRβ only) and C (constant) (142).  Each of these regions is encoded by a different 
gene segment, correspondingly called V, D, J and C.  So the TCR expressed at the T cell surface 
is formed by the association of a TCRα chain (Vα-Jα-Cα) with a TCRβ chain (Vβ-Dβ-Jβ-Cβ). 
 
The genes that encode the TCR alpha and beta chains respectively are located in two distinct 
chromosomal locations (143).  Within the TCR loci, multiple copies of the V, (D) and J gene 
segments are arranged in series.  In the TCRα locus, there are over 80 consecutive Vα gene 
segments, (Vα1, Vα2, Vα3…etc), followed by multiple Jα gene segments (Jα1, Jα2…etc) and a 
single Cα gene segment.  The TCRβ locus contains a series of Vβ gene segments, (Vβ1, Vβ2, 
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 Vβ3…etc), followed by two clusters of Dβ-Jβ-Cβ gene segments.  Each D-J-Cβ cluster contains 
multiple Jβ genes flanked by a single 5’ Dβ and a single 3’ Cβ gene. (i.e. Dβ1, Jβ1.1, 
Jβ1.2…Jβ1.6, Cβ1  and   Dβ2, Jβ2.1, Jβ2.2, Jβ2.3…Jβ2.7, Cβ2). 
 
These multiple gene copies probably arose over generations of evolution by gene duplication, 
and much of their sequence is very similar, often being referred to as the “framework” of the 
TCR.  However, considerable sequence variability exists in the parts of the V and J regions 
which interact with the cognate antigen-MHC complex.  These regions of so-called 
hypervariability are termed the complementarity determining regions (CDR)s.  CDR1 and CDR2 
are located in the variable gene segments; CDR3 is located at the junction of the V (D) and J 
gene segments (142). 
 
 
1.5.2. V-D-J DNA Recombination 
Each TCR is constructed from several pre-formed genetic units during T cell development in the 
thymus.  This occurs via a series of DNA recombination events which result in the random 
association of different V, D and J gene segments to form a full-length TCR (144-148).  For 
example, the MUC1-specific TCR discussed later in this chapter contains the gene segments 
Vα2.7-Jα49-Cα and Vβ6-Dβ2-Jβ2.5-Cβ2. 
 
Although the association of the VDJ gene segments is random, it is temporally highly regulated; 
the TCRβ chain is constructed first, followed by the TCRα chain.  The first DNA rearrangement 
aligns a Jβ gene segment next to the Dβ gene segment from that Jβ cluster (e.g. Dβ2 with Jβ2.5).  
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 Then a second rearrangement in the TCRβ locus introduces a Vβ gene segment into the Dβ-Jβ 
exon.  Any intervening Vβ, Dβ or Jβ gene segments are permanently excised from the 
chromosome of that particular T cell and can no longer be included in the T cell receptor 
expressed by that T cell.  The deleted portions of the TCR loci are retained in mature T cells as 
circularized DNA fragments known as TCR excision circles (149,150).  Multiple VDJ 
recombination events may be necessary to produce a complete TCRβ chain, expressed as one 
open reading frame.  The integrity of the TCRβ chain is tested by its ability to associate with a 
pre-TCRα chain in the pre-TCR complex (151).  If this association is successful, the pre-TCR 
will be expressed at the cell surface, which signals to the TCRα locus to begin V-J 
recombination.  Productive re-arrangement of the Vα-Jα gene segments results in expression of 
a full-length TCRα chain, which replaces the pre-TCRα chain in the final TCR complex. 
 
1.5.3. Allelic Exclusion 
Every T cell carries TCR loci on maternal and paternal chromosomes.  Therefore, developing T 
cells have the potential to execute V(D)J recombination in two TCRα loci and two TCRβ loci.  
If this were to happen, every T cell would carry two TCRα chains and two TCRβ chains.  
Random association of the TCRα and -β chains would result in the expression of four TCRs on 
the T cell surface, each with a different specificity.  To ensure that each T cell has only a single 
antigen-specificity, VDJ recombination is limited to only one TCRα and one TCRβ locus by a 
process termed allelic exclusion (152,153).  Once VDJ recombination has produced a full-length 
TCRβ chain, further VDJβ recombination is suppressed at that locus and at the TCRβ locus on 
the other chromosome.  Subsequent recombination of the TCRα genes is not affected by allelic 
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 exclusion of the TCRβ locus.  However, when a productive VJα re-arrangement is achieved, 
further VJα recombination at the TCRα locus is similarly suppressed. 
 
It is possible to take advantage of the allelic exclusion mechanism in order to express a TCR of 
known specificity in all T cells of a TCR-transgenic mouse.  The presence of pre-arranged TCR 
alpha and beta chains (even on a different chromosome from those which carry the endogenous 
TCR loci), and their expression in developing T cells, is sufficient to suppress VDJ 
recombination at the endogenous TCR loci (154).  Thus, the vast majority of mature T cells in a 
TCR-Tg mouse will express the cloned TCR of interest. 
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 2. CONTROL OF MUC1-SPECIFIC IMMUNITY BY CD4+ T LYMPHOCYTES 
 
2.1. Introduction 
 
MUC1-specific immune responses in cancer patients are, at best, weak and insufficient to halt 
the progression of the developing tumor.  Evidence suggests that CD4+ T cells become 
“tolerized” to MUC1, which is a self-molecule (50,51,137,155,156).  It is not yet clear whether 
all MUC1-specific T cells are centrally deleted or whether additional mechanisms of peripheral 
tolerance are at play.  As CD8+ T cells require help from CD4+ T cells in order to establish 
effective CTL memory (16,42), the lack of highly effective MUC1-specific Th cells in cancer 
patients is thought to be a major obstacle in generating effective anti-tumor immunity.   
 
This requirement for T cell help is exemplified by the quantitative and qualitative differences in 
the MUC1-specific immune responses that can be induced by vaccination of WT and MUC1-Tg 
mice.  MUC1-Tg mice express the human MUC1 gene under the control of its endogenous 
promoter, such that MUC1 is expressed with similar tissue distribution in MUC1-Tg mice as in 
humans (136).  Expression of MUC1 as a self-molecule in MUC1-Tg mice renders them tolerant 
to immunization with MUC1-100mer.  Vaccination protocols which elicit effective MUC1-
specific tumor immunity in WT mice yield only weak responses in MUC1-Tg mice and, 
compared with WT mice, and MUC1-Tg mice are more susceptible to challenge with MUC1+ 
tumors (50,51,137). 
 
When WT mice are immunized sub-cutaneously with DC that have been pre-loaded with MUC1 
peptide, they generate a robust MUC1-specific T helper (Th) response which provides assistance 
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 for all arms of the adaptive immune system (50).  In the presence of MUC1-specific T cell help, 
CTL from DC-immunized WT mice efficiently lyse MUC1+ tumors and B cells undergo 
efficient antibody isotype switching to produce high titers of MUC1-specific serum IgG that can 
be detected in sera.  The same DC vaccine administered to MUC1-Tg mice induces only weak 
MUC1-specific CTL responses and low-titer serum IgM.  MUC1-specific tolerance is 
particularly evident in the CD4+ T cell compartment; all but the most potent vaccination 
protocols fail to elicit MUC1-specific CD4+ T cell responses in MUC1-Tg mice (50,140,157).  
The lack of MUC1-specific Th responses in MUC1-Tg mice is thought to be responsible for the 
poor responses that are observed in the other arms of the adaptive immune system. 
 
This is evidence to suggest that the MUC1-specific Th compartment that is compromised in 
MUC1-Tg mice can be restored to full functionality by supplying CD4+ T cells from WT mice 
(51).  This goes some way to proving that CD4+ T cells are the key to eliciting effective 
immunity to MUC1.  However, in those particular studies, it was not determined whether the 
transferred Th cells were actually MUC1-specific.  Therefore, the observed improvement in the 
MUC1-specific CTL response may have been due to heterologous help (i.e. Th cells specific for 
another antigen besides MUC1).   
 
Our goal was to determine the effect that MUC1-specific CD4+ T cells have on MUC1-specific 
immune responses. The data presented here show that provision of WT MUC1-specific Th cells 
does indeed result in improved immunity to MUC1 in MUC1Tg mice.  In addition, we show 
that, while immunization of MUC1-Tg mice with MUC1 fails to stimulate MUC1-specific Th, 
potent MUC1-specific Tregs are induced which are capable of suppressing MUC1-specific 
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 immune responses both in vitro and in vivo.  These results indicate that one mechanism of 
“tolerance” to MUC1 in Muc1 Tg mice is the imbalance between MUC1-specific Th and Treg 
cells, in favor of Tregs.  We show that this skewing toward a regulatory response can be 
overcome by supplying Th cells from WT mice. 
 
 
2.2. Methods 
 
2.2.1. Mice and cell cultures 
C57BL/6 MUC1-Tg mice were obtained from Dr S. Gendler (Mayo Clinic, Scottsdale, AZ) and 
bred in the animal facility of the Hillman Cancer Center at University of Pittsburgh School of 
Medicine.  B6.PL-Thy1a/Cy mice were purchased from the Jackson Laboratory (Bar Harbour, 
MA).  All mice were maintained in a specific pathogen free environment and treated in 
accordance with the guidelines of the IACUC of the University of Pittsburgh.   
 
With the exception of the 44-22-1 hybridoma, all mouse cells were cultured in complete DMEM 
(cDMEM) containing 10%FBS, Penicillin & Streptomycin, L-Glutamine, Na Pyruvate, Non-
Essential Amino Acids, Hepes Buffer, and β-2 Mercaptoethanol (amounts), plus other additives, 
as indicated below. 
 
2.2.1.1. Generation of Bone Marrow Dendritic Cells and Vaccination of mice 
Femurs and tibiae were removed from female C57BL/6 mice.  The epiphyseal plates were cut off 
and bone marrow flushed out with cDMEM using a syringe.  Cells were centrifuged at 300g for 
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 5 minutes and the pellet resuspended and triturated in 1ml RBC lysis buffer (Sigma, MO) for 
1min, after which 9mL cDMEM was added to dilute the lysis buffer.  Cells were centrifuged and 
washed another three times, then resuspended at 1.5-2 million cells/mL in cDMEM containing 
10ng/ml each of GM-CSF and IL-4 (a generous gift from Immunex, WA) and transferred to T75 
tissue culture flasks (BD Biosciences, CA) at 15-20 million cells in 10mL.  Cells were fed every 
two days by adding 5ml cDMEM containing 10ng/ml GM-CSF and IL-4.  On day 7 of culture, 
cells were harvested using 2mM EDTA and separated by density centrifugation using Nycoprep 
1.068 (Accurate Chemical, NY).  Purified DC were loaded for 4-6 hours in polypropylene tubes 
with 20-50ug/mL synthetic MUC1 100mer in cDMEM at no more than 3 million cells per mL.  
Loaded DC were washed twice with PBS and resuspended in PBS at 5x105 cells/mL.  Soluble 
100mer was added at 500μg/ml.  Mice were injected subcutaneously in the right flank with 200μl 
PBS containing 105 loaded DC and 100μg soluble 100mer.  Boosts were administered two weeks 
apart. 
 
2.2.1.2. Preparation of LN and spleens 
Spleens and inguinal lymph nodes were mechanically disrupted with a syringe plunger and 
single cell suspensions in cDMEM obtained by passing them through a 70μm cell strainer.  
Splenocytes only were then centrifuged, and the cell pellets resuspended and triturated in 1ml 
RBC lysis buffer (Sigma, MO) for 1min, after which 9mL cDMEM was added to dilute the lysis 
buffer.  Cells were washed three times in DMEM, counted and used in the assays described 
below. 
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 2.2.1.3. T cell culture and in vitro stimulation 
LN/spleen cells were seeded at 3x106 cells per well of a in 24-well tissue culture plates (Linbro) 
in cDMEM containing 20U/mL muIL-2 (Immunex, WA).  On day0 of the culture, 100mer 
pulsed BMDC were added at 3x105 cells per well to stimulate the proliferation of MUC-specific 
T cells.  Cultures were fed every 2 days by replacing half of the media with fresh cDMEM 
containing 20U/mL mIL-2.  T cell function was tested for cytotoxicity on day 5 and cytokine 
production on day 7, as described below.  As a positive control for stimulation, cells were treated 
with Phorbol myristate acetate (PMA) and Ionomycin (Sigma, MO). 
 
2.2.2. Flow Cytometry 
LN/spln cells were prepared as described above and maintained on ice for the duration of the 
staining procedure.  Cells were washed and resuspended in FACS buffer (2% FBS in PBS) at 5 
to 10 million cells/ml and transferred to a 96-well Greiner microtiter plate (Fisher, PA) at 5x105 
to 106 cells (100μl) per well.  Surface FCR was blocked for by incubating cells for 15mins with 
anti-CD16/CD32 MAb, diluted 1:50 in FACS buffer.  Without washing, cells were then stained 
for 30mins using antibodies specific for various surface antigens, as indicated (e.g. CD3, 
CD4…).  All commercial antibodies used for flow cytometry were purchased from BD 
Biosciences (San Jose, CA) or eBioscience (San Diego, CA) and were added to the blocked cells 
at 2:50 dilution in FACS buffer (final dilution was therefore 1:50).  After washing three times in 
FACS buffer, cells were re-suspended in 300μl FACS buffer and analyzed on an LSR II Flow 
Cytometer (BD Biosciences), running FACSDiva software.  FACSorting was performed with a 
FACSAria (BD Biosciences).  If necessary, cells were stored overnight at 4oC in FACS buffer 
containing 1% PFA before analysis the next day. 
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 2.2.2.1. FoxP3 stain. 
LN/splenocytes were stained for surface CD3, CD4 and CD25 as described above.  Cells were 
stained intracellularly for FoxP3 using a mouse FoxP3 staining kit (eBioscience, CA), as per the 
instructions, except with the omission of the PBS wash after the Fix/Perm step.  The FoxP3 
antibody was applied to cells at 1:50 dilution for 30mins.  Cells were then washed three washes 
in Perm/Wash buffer and resuspended in FACS buffer for analysis. 
 
2.2.2.2. Intracellular Cytokine Staining 
LN or spleen cells were, prepared as above, were stimulated for 6-12 hours in the presence of 
Golgi Plug (Brefeldin A) with either MUC1-pulsed DC (10:1 ratio of lymphocytes to DC) or 
with PMA/Ionomycin.  After stimulation, cells were washed with PBS containing 2% FBS and 
stained for 30mins for surface markers using antibodies specific for CD3, CD4 or CD8, as 
described above.  Cells were washed three times with FACS buffer.  ICS was performed using a 
Cytofix/Cytoperm kit (BD Biosciences), as per the manufacturer’s instructions.  Cells were 
permeabilized by resuspending in cytofix/cytoperm solution for 20mins.  After two washes with 
PermWash solution, intracellular FCR was blocked with anti-CD16/CD32.  Without washing, 
cells were stained intracellularly for 30mins with antibodies specific for IFNγ, TNFα, IL-10 or 
IL-5 (antibodies at this stage were diluted 1:50 in PermWash).  After intra-cellular staining, cells 
were washed thrice with PermWash and then resuspended in FACS buffer. 
 
2.2.3. IFNγ ELISA 
All cytokine ELISA were performed using an OptEIA ELISA set (BD Biosciences, CA), 
following the manufacturer’s instructions.  In brief, 105 LN or spleen cells were stimulated in 
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 triplicate by 104 BMDC in a Costar sterile 96-well U-bottom micro-titer plate (Corning, NY) for 
24-48 hours, as indicated, in a total volume of 200μl/well.  Immulon 4HBX plates (Fisher) were 
pre-coated overnight with IFNγ capture antibody and pre-blocked for one hour with PBS 
containing 10% FBS.  100μl of culture supernatant was transferred to the pre-coated ELISA plate 
and incubated for 2hr at room temperature.  After washing the plates with 0.05% TWEEN20, 
100ul working detector (biotinylated IFNγ detection antibody plus avidin-HRP) solution was 
added for 1hr.  Cells were washed again and 100μl TMB substrate (BD Biosciences, CA) added 
and incubated for up to 30 min in the dark.  The reaction was stopped by adding 50μl 2N H2SO4.  
Absorbance at 450nm was recorded using an MRX Revelation ELISA plate reader 
(ThermoLabSystems, MA). 
 
2.2.4. 2.3.5 Serum Ig ELISA 
Mice were bled from the carotid artery immediately after sacrifice.  Serum was separated by 
centrifugation for 5 minutes at 5,000g and stored at 4oC.  ELISA was performed at room 
temperature.  Immulon 4HBX plates (Fisher) were coated overnight at with MUC1 100mer 
(1μg/50μl in PBS) or 2.5%BSA.  After coating, plates were washed with 200μl PBS and then 
blocked for 1hr with 100μl 2.5% BSA.  Sera (diluted appropriately in 2.5% BSA) were added to 
the plate in triplicate at 50μl/well for 1hr.  Plates were washed several times with 200μl Tween20 
(0.1% in PBS).  50μl HRP-conjugated anti-mouse Ig detection antibody (Southern Biotech, AL) 
diluted 1:500 was added for 1hr.  Plates were washed again in Tween20, then 100μl TMB 
substrate (BD Biosciences, CA) added for 30mins in the dark, after which the reaction was 
stopped by adding 50μl 2N H2SO4.  Absorbance at 450nm was read using an MRX Revelation 
ELISA plate reader (ThermoLabSystems, MA), with kind permission from Dr Karen Norris. 
35 
  
51Cr-release cytotoxicity assay 2.2.5. 
2.2.6. 
106 RMA and RMA-MUC1 target cells were labeled for 1hr with radioactive 51Cr (vendor), then 
washed three times with DMEM, resuspended in cDMEM at 106 cells/ml and seeded in a 96-well 
V-bottom microtiter plate at 2,000 cells per well in 100μl.  Responder LN/spleen cells were 
added in triplicate in cDMEM in the indicated quantities (2.4x104 to 105) for 4-6 hours.  
Supernatants containing released 51Cr were harvested and analysed on a Cobra II auto-gamma 
counter (Perkin-Elmer, MA).  Spontaneous lysis was determined by testing supernatants from 
wells containing target cells only.  Total lysis (i.e. complete lysing of all target cells) was 
determined from well in which HCl or H2S04 was added to the target cells.  Specific lysis was 
calculated as (lysis – spontaneous lysis)/(total lysis – spontaneous lysis).  Averages of triplicates 
were plotted. 
 
Adoptive T cell Transfers 
Donor mice were immunized with 100mer-pulsed DC, as described above.  Two weeks after 
immunization, LN and spleen were removed from donor mice and single cell suspensions 
prepared as described above.  CD4+ T lymphocytes were positively selected by magnetic 
antibody cell sorting (MACS) using CD4 (L3T4) Microbeads (Miltenyi Biotech, CA).  Purified 
CD4+ T cells were washed and resuspended in sterile PBS.  Prior to injection of T cells, mice 
were placed under a heat lamp to induce vasodilation.  Then 1 x106 - 5 x106 CD4+ T cells in 
200μl PBS were injected into mice via the lateral tail vein using a syringe with a 27½ gauge 
needle.   
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 2.3. Results 
 
2.3.1. MUC1-Tg mice respond only weakly to immunization with MUC1, compared to 
WT mice 
 
In a previous study conducted in our laboratory (50), a DC-based immunization protocol 
highlighted the vast difference in the magnitude of MUC1-specific CD4+ T cell responses 
between MUC1-Tg and WT mice, the basis for which was not elucidated.  When designing 
experiments to investigate this problem and in general the effect that MUC1-specific CD4+ T 
cells have on other arms of the MUC1-specific immune response, we reasoned that using this 
same DC vaccine would be an appropriate method of generating MUC1-specific CTL responses 
that are dependent on T cell help.  These Th-dependent CTL would reveal any intrinsic 
differences in MUC1-specific CD4 cells from MUC1-Tg and WT mice. 
 
To confirm in an independent study, that WT and MUC1-Tg mice exhibit the markedly disparate 
immune responses to the MUC1/DC vaccine as previously shown, WT and MUC1-Tg mice were 
immunized subcutaneously with dendritic cells that had been pulsed in vitro with synthetic 
MUC1 100mer peptide.  Two weeks after vaccination, inguinal lymph nodes, spleens and sera 
were collected and analyzed for the presence of MUC1-specific immune responses. 
 
In keeping with previous reports, WT mice mounted strong humoral and cellular immune 
responses to MUC1 immunization, whereas only weak CD8 T cell responses were observed in 
MUC1-Tg mice (fig2-1).  The MUC1-DC vaccine induced potent CD4+ T cell responses in WT 
mice, but virtually undetectable numbers of responding CD4+ T cells in MUC1-Tg mice (fig2-
1a).  The absence of MUC1-specific Th cells in MUC1-Tg mice is associated with weak MUC1-
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 specific CD8 T cell responses, measured by both IFN-γ production (fig2.1a) and inefficient lysis 
of MUC1+ tumors (fig2.1b).  The most striking difference between WT and MUC1-Tg mice is in 
antibody class switching to the IgG isotype (fig 2.1c).  As this process is normally initiated via 
interaction of the B cells with antigen-specific Th cells (158), the lack of MUC1-specific serum 
IgG in MUC1-Tg mice confirms the absence of MUC1-specific T cell help. 
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Figure 2-1. MUC1-Tg mice are tolerant to immuzation with MUC1-loaded DC 
WT and MUC1-Tg mice (4 each) were immunized and boosted sub-cutaneously with 105 MUC1-loaded DC.  Two 
weeks post-boost, DLN and sera were isolated, pooled and tested.  A) IFNγ production.  LN cells were stimulated 
for 6hr with MUC1-loaded DC, PMA and Ionomycin in the presence of brefeldin-A, then stained for surface CD4 
and CD8 and intracellular IFNγ.  B) Specific lysis of the MUC1+ tumor RMA-MUC1.  LN cells were incubated with 
51Cr-labelled RMA or RMA-MUC1 targets for 4 hours in triplicate.  C) MUC1-specific serum IgG.  Sera from 
immunized mice were incubated on ELISA plates coated with MUC1 100mer then blotted with anti-mouse IgG. 
 
38 
 2.3.2. Transfer of WT CD4+ T cells suppresses MUC1-specific immune responses in 
MUC1-Tg mice 
 
Since the previous experiments pointed to the CD4+ T cells as the root cause of poor MUC1-
specific immunity in MUC1-Tg mice we reasoned that MUC1-Tg mice should mount improved 
immune responses if provided with fully functional MUC1-specific CD4+ T cells from WT 
donor mice.  We also expected that  immunizing the WT donor mice prior to adoptive transfer 
would ensure that the transferred CD4+ T cells were primed to MUC1 in the absence of any 
tolerizing factors that might be present in the MUC1-Tg mouse, and could then effectively help 
the recipient mice mount effective anti-MUC1 immunity. 
 
Two weeks prior to adoptive transfer, WT donor mice were vaccinated with MUC1-pulsed DC.  
As shown in fig2-1, this immunization protocol induces IFNγ-producing CD4+ T cells, which 
would be expected to provide help to MUC1-specific B cells and CD8 T cells.  Two weeks after 
DC-immunization, CD4+ T cells were isolated from the WT donors and adoptively transferred 
via the tail vein into naïve MUC1-Tg mice, which were subsequently immunized and boosted 
with MUC1-loaded DC on days 1 and 15 post-T cell transfer.  MUC1-specific immune responses 
were tested two weeks after the boost. 
 
Contrary to expectations, adoptive transfer of primed CD4+ T cells from WT mice further 
reduced the ability of MUC1-Tg mice to respond to subsequent immunization (fig 2-2).  The 
transferred CD4+ T cells suppressed both cellular and humoral immune responses to the DC-
MUC1 vaccine (fig 2-2).  Cells isolated from the LN of adoptively transferred MUC1-Tg mice 
contained reduced numbers of IFNγ producing CD8 and CD4+ T cells (fig 2-2a), and exhibited a 
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 reduced capacity to specifically lyse the MUC1+ tumor RMA-MUC1 (fig 2-2b).  In addition, 
there were significantly lower levels of MUC1-specific IgG in the sera of these mice (fig 2-2c), 
indicating that antibody isotype class switching by MUC1-specific B cells was also suppressed.  
No detectable IL-10 or IL-5 was produced by these T cells (not shown). 
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Figure 2-2. Primed WT CD4+ T  cells suppress MUC1-specific immune responses 
WT donor mice were immunized with MUC1-DC.  Two weeks later, CD4+ T cells were transferred to MUC1-Tg 
mice.  Recipients and untreated controls were then immunized with MUC1-DC.  Two weeks after immunization, LN 
and sera were pooled (4 mice/group) and tested.  A & B; IFNγ production LN cells were stimulated in vitro for 6hrs 
in the presence of brefeldin A, then stained for surface CD8, CD4, and intracellular IFNγ.  C; Lysis of RMA-MUC1 
tumor cells. LN cells were incubated with 51Cr-labelled RMA or RMA-MUC1 targets for 4 hours in triplicate. D; 
MUC1-specific serum Ig ELISA.  Sera from immunized mice were incubated on ELISA plates coated with MUC1 
100mer then blotted with polyclonal anti-mouse Ig. 
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 2.3.3. 
2.3.4. 
Phenotype of DC used for immunizations 
In an attempt to determine why this adoptive immunotherapy had suppressed the immune 
response in MUC1-Tg recipients, we first decided to investigate the phenotype of the BMDC 
used to vaccinate the mice.  As immature DC have been reported to cause immunological 
tolerance (35,159), we wished to confirm that our standardized method of generating DC from 
bone marrow precursors did indeed generate mature DC, as intended.  A sample of the DC used 
for immunization was stained for the presence of various surface markers of DC activation and 
maturity: CD11c, CD80, CD86, CD40, I-Ab, and analysed by flow cytometry.  All of these 
molecules were expressed by the DC (fig2-3), indicating that those DC used to immunize our 
mice were mature DC that provided the co-stimulatory molecules necessary for priming of naïve 
T cells.  However, the DC population was heterogeneous, and contained both high and low 
expressors of these costimulatory molecules. 
 
 
Mature DC induce FoxP3+ Regulatory T cells 
Given the well-documented immuno-suppressive effect of CD4+ regulatory T cells (Tregs) 
(62,64,70), we wondered if the immune suppression observed after adoptive transfer was due to 
the presence of Tregs, the hypothesis being that vaccination of the WT donor mice had caused an 
increase in the numbers of MUC1-specific Tregs in the population of transferred CD4+ T cells.  
In the first attempt to test this hypothesis, we took advantage of a remaining WT ‘donor’ mouse 
that had been vaccinated at the same time as the donor mice in the previous experiment.  The 
number of FoxP3+ CD4+ T cells in lymphoid organs was determined by flow cytometry and 
compared to a naïve mouse. 
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Figure 2-3. Phenotype of DC used for immunization 
BMDC were cultured in cDMEM containing GM-CSF and IL-4 for 7 days.  DC were then purified by centrifugation 
over Nycoprep and stained with MAbs specific for CD11c (A), CD80 (B), CD86 (C), CD40 (D) or I-Ab (E).  
CD11c+ cells were gated and analysed for expression CD80, CD86 and I-Ab.  Red lines, isotype control antibody; 
Green lines, specific staining. 
 
 
 
As the original donor mice had been boosted prior to isolation of the transferred CD4+ T cells, 
this ‘donor’ mouse was given another boosting injection of MUC1-loaded DC.  Two weeks after 
the boost, inguinal lymph nodes were removed and analysed by flow cytometry for the presence 
of CD3+CD4+FoxP3+ Tregs.  Not only were Tregs present in the population of CD4+ T cells, 
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 their numbers were two-fold higher than in a non-immunized control mouse (fig 2-4).  This 
suggested that FoxP3+ Tregs were present in the population of CD4+ T used in the previous 
adoptive transfer study and that vaccination of the donor mice with MUC1-loaded DC had 
induced the expansion of Tregs. 
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Figure 2-4. FoxP3+ Tregs in DC-immunized WT donor mice 
A) LN cells were isolated from WT mice two weeks after immunization with MUC1-DC and stained for surface 
CD4, CD25 and FoxP3.  Gating on CD4+ cells (upper panel), CD25 was plotted against FoxP3 (lower panel).   
B) LN cells were stained for surface CD3, CD4 and FoxP3.  Gating on CD3+ cells (upper panel), CD4 was plotted 
against FoxP3 (lower panel). 
C) The number of CD3+CD4+FoxP3+ cells was enumerated and is represented as percentage of total LN cells. 
 
 
This preliminary experiment shows a clear difference in the proportion of Tregs in the lymph 
nodes of naïve and immunized mice.  However, a repeat experiment was warranted to test a more 
significant number of mice.  To this end, WT mice were immunized with MUC1-loaded DC and 
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 the numbers of lymphoid Tregs compared with those in age-matched naïve mice.  As before, an 
increased proportion of FoxP3+ Tregs were observed in the spleens and LN of DC-immunized 
mice, compared with naïve controls (fig 2-5), confirming the original conclusion that vaccination 
of donor mice caused an expansion of Tregs.  The presence of increased numbers of Tregs in the 
pool of adoptively transferred CD4+ T cells would explain why the recipient MUC1-Tg mice 
exhibited a reduced response to subsequent vaccination. 
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Figure 2-5. DC-induced expansion of Tregs in age-matched WT mice 
6 month old WT mice were injected sub-cutaneously with MUC1-pulsed DC.  Two weeks after immunization, LN 
and spleens were isolated and cells stained on the surface for CD3 and CD4, and intracellularly for FoxP3.  The 
number of FoxP3+ cells is expressed as a percentage of CD4+CD3+ cells. 
 
 
In the first experiment, Tregs were increased 4-fold in the immunized mouse (fig2-4), whereas 
only a 1.5-fold increase was observed in the repeat experiment (fig2-5).  One explanation for this 
discrepancy is that all of the mice tested in the repeat experiment were six months old, whereas 
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 those used in the first experiment were not age-matched; the original immunized ‘donor’ mouse 
was 10months old and was compared with a 6 month old naïve control mouse.  Given that age 
has a significant effect on the magnitude of immune responses (160,161), it is possible that the 
age difference between the first two mice may have contributed to the observed change in 
numbers of Tregs.  To address this issue, we set out to separate the potential influences that old 
age and DC-immunization might respectively exert on the conversion of naïve CD4+ T cells into 
Tregs.  Mice were immunized with MUC1-loaded DC at 5 and 9 months of age, and the numbers 
of lymphoid Tregs enumerated two weeks after vaccination.  LN from old mice contained almost 
twice as many FoxP3+ Tregs than those from younger mice (fig 2-6), indicating that DC-
mediated expansion of Tregs is exacerbated in older donor mice. 
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Figure 2-6. Induction of Tregs in old vs young mice 
WT mice aged 3 or 6 months were immunized and boosted subcutaneously with MUC1-pulsed DC at two week 
intervals.  Two weeks after the boost, inguinal LN were removed and stained for surface CD3 and CD4, and 
intracellular FoxP3.  Relative numbers of FoxP3+ cells are expressed as % of CD3+CD4+ cells. 
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2.3.5. DC-mediated expansion of Tregs is MUC1-specific 
 
We next set out to confirm that the DC-induced Tregs do respond to MUC1-specifically and are 
not induced by other antigens presented by the DC (e.g. bovine serum proteins in the culture 
medium), or even by DC independently of antigen presentation.  To this end, WT mice were 
immunized with MUC1-pulsed DC, un-loaded DC, or PBS.  As before, increased numbers of 
FoxP3+ Tregs were observed in the DLN of mice receiving MUC1-loaded DC.  Mice receiving 
unloaded DC had the same baseline level of Tregs as control mice injected with PBS (Figure 2-
7).  This confirms that the expansion of Tregs observed after immunization with DC is dependent 
upon the presence of MUC1, suggesting that those responding Tregs are MUC1-specific. 
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Figure 2-7. MUC1-specific expansion of Tregs 
Mice were immunized with unloaded DC or DC that were loaded in vitro for 4 hours with 50μg/ml MUC1 100mer,.  
Control mice were injected subcutaneously with PBS (the vehicle for the DC vaccine).  Two weeks after 
immunization, DLN were harvested and stained for CD3, CD4 and FoxP3. 
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 MUC1-expanded Tregs suppress MUC1-specific T cells in vitro 2.3.6. 
 
The data shown so far indicate that CD4+ T cells from DC-immunized WT donors suppress 
MUC1-specific immune responses in vivo and that the pool of adoptively transferred CD4+ T 
cells contains FoxP3+ CD4+ T cells that were expanded in a MUC1-specific fashion.  It therefore 
seems reasonable to assume that the FoxP3+ T cells are Tregs and that they are the cause of the 
immune suppression observed after the adoptive transfer. 
 
 
In order to state this conclusively, it was necessary to prove in a functional assay that the FoxP3+ 
T cells, when isolated from the other adoptively transferred CD4+ T cells, maintain the ability to 
suppress MUC1-specific T cell responses.  As FoxP3 is an intracellular molecule, the putative 
Tregs could not be purified based on FoxP3 expression.  However, as all of the CD4+CD25+ cells 
detected in the immunized donor mice are FoxP3+ (fig 2-4), isolation of CD3+CD4+CD25+ triple-
positive cells provides a pure population of the putative FoxP3+ Tregs. 
 
Accordingly, CD3+CD4+CD25+ T cells were FACSorted from lymph nodes and spleens of 
immunized WT mice.  Their ability to suppress MUC1-specific immune responses was tested by 
adding them in varying amounts to MUC1-primed CD8+ responders and stimulating the co-
culture with DC that were pre-loaded with MUC1.  These CD4+CD25+ T cells isolated from 
MUC1-immunized WT mice effectively suppressed the MUC1-specific production of IL-2 by 
CD8+ T cells (fig 2-8).  This suggests that the FoxP3+CD4+CD25+ T cells, induced MUC1-
specifically by DC, are indeed Tregs. 
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Figure 2-8. Putative Tregs suppress MUC1-specific T cells in vitro 
105 responder CD8 T cells were purified from MUC1-DC-immunized WT mice and stimulated in vitro for 24hrs 
with 104 MUC1-loaded DC in the presence or absence of CD4+CD25+ T cells purified from the same immunized 
WT mice.  IL-2 production was measured in culture supernatants by ELISA. 
 
 
The data presented so far collectively indicate that mature DC presenting MUC1 epitopes induce 
the expansion of MUC1-specific Tregs.  This is surprising, as MUC1-loaded DC also prime 
naïve T cells to become effective Th cells, which form part of an effective MUC1-specific 
immune response capable of rejecting MUC1+ tumors (Fig 2-1) and (50). 
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 2.3.7. MUC1-specific Tregs predominate in MUC1-Tg mice 
In the MUC1-Tg mouse, MUC1-specific Th responses are virtually undetectable (fig2-1) 
(50,51,137).  We wondered whether, in the absence of MUC1-specific Th responses, MUC1-
loaded DC will still induce MUC1-specific Tregs and, if so, what the implications are for the 
other arms of the immune system.  To answer these questions, MUC1-Tg mice were immunized 
with MUC1-loaded DC and their spleens analysed for the presence of FoxP3+ Tregs.  
Surprisingly, immunization of MUC1-Tg mice with MUC1-loaded DC causes a similar 
expansion of FoxP3+ Tregs as seen in WT mice (fig 2.9).   
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Figure 2-9. Expansion of Tregs in MUC1-Tg mice 
WT and MUC1-Tg mice were immunized and boosted with MUC1-loaded DC.  Two weeks 
after the boost, splenocytes were isolated and stained for FoxP3.  Numbers of FoxP3+ cells are 
expressed as a percentage of splenic CD4+ T cells. 
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 When CD4+ T cells from immunized MUC1-Tg mice were adoptively transferred to WT mice, 
they suppressed MUC1-specific immune responses by the same degree as CD4+ T cells from WT 
mice (fig 2-10).  Therefore, MUC1-specific Tregs respond normally in MUC1-Tg mice and are 
potent suppressors of MUC1-specific immune responses. 
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Figure 2-10. MUC1-Tg CD4+ T cells suppress WT MUC1-specific immune responses 
WT and MUC1-Tg donor mice were immunized with MUC1-loaded DC.  Two weeks later, their CD4+ T cells were 
purified and adoptively transferred to WT recipients (5x106 cells/mouse).  Recipient mice were immunized and 
boosted with MUC1-DC.  Two weeks post-boost, LN and blood samples were tested:  A and B) IFNγ production by 
CD8+ and CD4+ T cells, measured by Intracellular Cytokine Staining.  C) MUC1-Specific lysis of RMA-MUC1 
tumor.  D) MUC1-specific serum IgG1 ELISA. 
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 2.3.8. Adoptive immunotherapy with Treg-depleted WT Th cells improves MUC1-
specific immunity in MUC1-Tg mice 
 
The presence of MUC1-specific Tregs and concomitant absence of MUC1-specific Th cells in 
MUC1-Tg mice suggests that there is an imbalance in the CD4+ T cell compartment such that the 
MUC1-specific Treg component outweighs the Th.  This might account for the poor CTL seen in 
these mice (fig2-1).  We modified our initial hypothesis that transfer of CD4+ T cells from WT 
mice would improve MUC1 specific responses in MUC1 Tg mice to the new hypothesis that 
shifting the balance in favor of MUC1-specific T cell help should improve the CD8+ T cell 
response to MUC1. 
 
To test this modified hypothesis, CD4+CD25- Th cells from MUC1-immunized Thy1.1+ 
congenic WT donors were purified by MACS-depletion of CD4+CD25+ Tregs and adoptively 
transferred into MUC1-Tg mice.  Recipient MUC1-Tg mice were subsequently vaccinated with 
MUC1-loaded DC and then evaluated for MUC1-specific immune responses. 
 
After transfer of CD25- CD4+ Th cells, MUC1-Tg mice exhibited improved MUC1-specific 
immune responses, of similar magnitude to those seen in WT mice (Fig 2-11).  IFN-γ production 
by both CD8 and CD4 cells was increased in MUC1-Tg mice that received WT Th cells, 
whereas MUC1-Tg mice that received total CD4+ T cells exhibited suppressed responses, as 
shown earlier (fig2-2).  The IFNγ-producing CD4+ T cells observed in the spleens of MUC1-Tg 
recipients of WT Th cells must be endogenous T cells, as Thy1.1+ donor T cells could not be 
detected in the recipient mice (data not shown).  This indicates that the adoptive transfer of 
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 functional Th cells provided help for both CD8 and CD4+ T cells in MUC1-Tg recipients, such 
that tolerance of the host CD4+ T cells to MUC1 was broken. 
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Figure 2-11. Purified WT Th cells break tolerance in MUC1-Tg mice 
CD4+ T cells, or Th cells depleted of CD25+ Tregs, were transferred from MUC1-DC immunized Thy1.1+ mice to 
MUC1-Tg mice.  Recipient MUC1-Tg mice, and non-transferred WT controls were immunized and boosted once 
with MUC1-loaded DC.  Ten days after the boost, DLN cells were harvested, restimulated in vitro with MUC1-
loaded DC.  7days after restimulation, cells were stimulated again with PMA and ionomycin and IFNγ responses 
measured by intracellular cytokine staining, gating on CD4+ or CD8+ T cells.  
 
 
 
2.4.  Discussion 
 
2.4.1. Th:Treg imbalance in MUC1-Tg mice maintains MUC1-specific “tolerance” 
The data presented here establish an important role for CD4+ T lymphocytes in augmenting and 
regulating immune responses to the tumor antigen MUC1.  The two components of the CD4+ T 
cell compartment, Th and Tregs, have opposing effects.  In WT mice, MUC1-specific Tregs are 
balanced by intact Th cell compartment, such that the DC-based MUC1 vaccine establishes 
effective MUC1-specific immunity.  However, such balance does not exist in MUC1-Tg mice.  
When the MUC1-specific Tregs run unopposed by Th cells, MUC1-specific CTL and antibody 
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 responses are suppressed (figs2-1 & 2-2), resulting in susceptibility to MUC1+ tumors 
(50,51,137).  When MUC1-Tg mice are provided with functional Th cells by adoptive transfer, 
they generate improved MUC1-specific immune responses.  This indicates that effective tumor 
immunity is dependent upon the relative balance of help and regulation. 
  
Although MUC1 expression in the peripheral tissues is restricted to the apical surface of 
epithelia, it is still a self-molecule.  A recent study has shown that expression of peripheral self-
antigens by thymic epithelial cells causes the deletion of self-reactive effector T cells in the 
thymus without affecting the development of Tregs (162), which suggests that the two sub-types 
of CD4+ T cells may be selected in the thymus by different mechanisms.  The Tregs described 
here were induced by immunizing mice with an unglycosylated form of MUC1, suggest that 
these Tregs are specific for the unglycosylated MUC1 tandem repeat peptide sequence.  It is 
possible that presentation of unglycosylated MUC1 epitopes in the thymus could cause the 
deletion of MUC1-specific Th cells from the repertoire, while Tregs would exit into the 
periphery.  This would account for the Th:Treg imbalance observed in MUC1-Tg mice. 
 
One way to avoid this problem would be to immunize with forms of MUC1 that carry tumor-
specific glycosylations, such as TF and TN antigens (87,122,123).  Even if the MUC1 gene is 
expressed thymically, these tumor-associated MUC1 glycoforms should not be produced in the 
thymus, as it does not share the exact repertoire of glycosyl transferases with the tumor.  CD4+ T 
cells specific for TN-MUC1 or TF-MUC1 should not be subjected to mechanisms of central 
tolerance.  Hence, an improved MUC1 vaccine would use forms of MUC1 that carry tumor-
specific oligosaccharides, such as Tn or TF antigens. 
2.4.2. Adoptive immunotherapy with Th cells breaks tolerance in MUC1-Tg mice 
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 The lack of a MUC1-specific helper T cell response is clearly an important factor in the weak 
immune responses that MUC1 vaccines elicit in MUC1-Tg mice.  MUC1-specific immune 
responses were improved in these mice by the adoptive transfer of functional Th cells from WT 
mice (fig2-11).  This indicates that generation of MUC1-specific Th responses is fundamental to 
generating effective anti-tumor immunity.  Furthermore, adoptive immunotherapy with WT Th 
cells resulted in detectable MUC1-specific Th responses in MUC1-Tg mice.  Since the 
responding CD4+ T cells were not the transferred Thy1.1+ Th cells, this result indicates that help 
was also provided for the endogenous Th cells in the MUC1-Tg mice.  This suggests that, if the 
right signals can be provided exogenously, it is possible to break the MUC1-specific tolerance 
that exists in the CD4+ T cell compartment of MUC1-Tg mice and, more importantly, cancer 
patients. 
 
2.4.3. Do Tregs survive adoptive transfer better than Th? 
The response of MUC1-specific CD4+ T cells to stimulation by DC involves both helper and 
regulatory cells.  The data presented in this chapter indicate that, in addition to stimulating potent 
MUC1-specific immunity in WT mice, presentation of MUC1 by DC leads to the induction of 
FoxP3+ Tregs (fig2-4, 2-7, 2-8).  The net outcome of immunizing WT mice with MUC1-loaded 
DC is effective MUC1-specific immunity (fig2-1) and (50), and the presence of Tregs clearly is 
not detrimental to this.  The concomitant induction of MUC1-specific Th and Tregs by DC is 
therefore considered to be part of a balanced immune response, whereby Tregs induced in order 
to bring the ongoing immune response to a quiescent state after the pathogen has been cleared 
(34). 
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 However, this ‘balanced’ population of CD4+ T cells suppressed MUC1-specific immunse 
responses when adoptively transferred into MUC1-Tg mice.  This was particularly surprising 
because the same CD4+ T cell population provided effective helper function in the donor mouse.  
The fact that Tregs triumph over Th only after adoptive transfer suggests there is a selection 
pressure against the Th cells in the recipient mouse.  This was true whether the recipient mouse 
was WT or MUC1-Tg, so was independent of any tolerogenic mechanisms related to expression 
of self-MUC1.   
 
Several studies have shown that effector T cells do not survive well after adoptive transfer unless 
“space” is created in the recipient by non-myeloablative chemotherapy to allow homeostatic 
proliferation of adoptively transferred T cells (163).  Recent evidence indicates that Tregs 
express higher amounts of the anti-apoptotic molecule Bcl-2, causing them to be less susceptible 
to apoptosis than their Th counterparts (164).  Taken together with the data present here, these 
lines of evidence suggest that adoptively transferred Tregs may survive better than Th cells after 
adoptive transfer, and therefore suppress immune response of the recipient. 
 
 
2.4.4. Timing of vaccination with respect to age 
The preliminary observation that older mice appear to have even higher numbers of FoxP3+ 
Tregs has obvious implications for the timing of anti-cancer vaccines with respect to the age of 
the individual.  Further studies will need to be performed to determine whether this was due to 
impaired activation of MUC1-specific Th cells, enhanced proliferation of MUC1-specific Tregs, 
or whether it is simply reflective of a higher background number of Tregs, regardless of antigen-
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 specificity.  Whatever the outcome of these future experiments, there is a clear link between old 
age and increased numbers of Tregs.  Given that cancer is predominantly a disease of the aged, 
these preliminary data support the case for administering prophylactic cancer vaccines to high-
risk individuals at a young age. 
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3. GENERATION OF A MUC1-SPECIFIC TCR-TRANSGENIC MOUSE, “VFT” 
 
3.1. Requirement for a MUC1-specific TCR-Tg mouse 
 
In the past few decades a wealth of knowledge has been amassed regarding tumor-specific CD8+ 
T cells and their essential role in anti-cancer immunity.  Much less attention has been paid to 
tumor-specific CD4+ T cells.  The data in the previous chapter indicate that the inability of 
MUC1-Tg mice to mount effective MUC1-specific immune responses is caused by a dominance 
of MUC1-specific CD4+ Tregs over their Th counterparts.  The suppression of MUC1-specific 
immune responses caused by these Tregs was relieved by providing WT Th cells that had been 
primed to MUC1.  In order to conclusively prove that the improved immune response was due to 
the provision of MUC1-specific CD4+ Th cells, it was necessary to confirm that the responding 
CD4+ T cells (both Th and Tregs) are actually MUC1-specific.  Given the antigen-independent 
manner in which Tregs suppress other T cells, it is especially important to be sure of the antigen 
specificity of the CD4+ T cells under investigation. 
 
To focus our studies on MUC1-specific CD4+ T cells, we created a transgenic (Tg) mouse in 
which all of CD4+ T cells are specific for MUC1.  In the following chapter, we describe the 
cloning of an MHC Class II restricted T cell receptor (TCR) that is specific for a 12 amino acid 
peptide derived from the tandem repeat region of unglycosylated MUC1 100mer.  The genes 
encoding the TCR alpha and beta chains from the MUC1-specific, CD4+ T cell hybridoma, VF5 
(165) were cloned into TCR expression cassettes, pTα and pTβ (166).  In these cassette vectors, 
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 expression of the cloned TCR is controlled by the natural TCRα and -β promoters.  The MUC1-
specific TCR constructs were then used to generate the MUC1-specific TCR-Tg mouse strain, 
VFT.  Two initial experiments were performed with the VFT mouse to confirm the two main 
conclusions from the previous chapter: 
  1) Presentation of MUC1 peptides by DC causes the induction of MUC1-specific Tregs 
  2) Adoptive transfer of MUC1-specific Th cells restores MUC1-specific immune 
responses in MUC1-Tg mice. 
 
3.2. Generating the VFT mouse: Issues and Methodology 
2. Microinject TCRαβ into 
Thy1.1+ mouse embryos and 
implant into pseudopregnant
females
VF5
1. Clone MUC1-
specific TCRαβ
MUC1-specific 
VFT cells
TCR-Tg 
“VFT” mice
 
 
Figure 3-1 Making the VFT TCR-Tg mouse 
The VJα and VDJβ genes encoding the variable regions of a MUC1-specific TCR were amplified by PCR from the 
CD4+ T cell hybridoma, VF5 (165), and cloned into the TCR expression cassette vectors pTα and pTβ (166), 
respectively.  These TCR expression constructs were injected into embryos of Thy1.1+ mice to generate the MUC1-
specific TCR-Tg mouse strain, VFT, on a C57BL/6 Thy1.1+ congenic background. 
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 3.2.1. 
3.2.2. 
“Natural” Expression of the transgenic TCR: pTα/β expression cassettes 
 
We wanted to generate a mouse in which all CD4+ T cells express a T cell receptor specific for 
MUC1.  As these MUC1-specific T cells would be used to answer fundamental questions 
regarding T cell tolerance and immunity to the tumor antigen MUC1, it was important that 
expression of the TCRα and β transgenes is regulated correctly with respect to T cell 
development and function.  To achieve this, the alpha and beta chains of the MUC1-specific 
TCR were cloned into two TCR cassette vectors, pTα and pTβ respectively.  These vectors 
contain large fragments of genomic DNA derived from the TCRα and-β loci, which flank 
multiple restriction enzyme sites into which the TCR of interest is cloned (166) and (figs3-5 and 
3-8).  The genomic fragments of the plasmids contain the cis-acting promoter and enhancer 
elements necessary for correct developmental and tissue-specific expression of the cloned TCR 
chains.  In addition, pTα and pTβ already contain the corresponding TCR constant gene 
segments (Cα and Cβ, respectively).  It was therefore possible to clone just the rearranged V(D)J 
gene segments without the constant gene segment, and insert them into the vector.  This avoids 
having to clone several kb of intron that separate the V(D)J and C exons.  When cloning the VDJ 
genes from genomic DNA, inclusion of the splice donor site 3’ to the J gene segment allows 
correct splicing of the cloned VDJ segments to the constant gene segment encoded by the vector. 
 
 
VF5 hybridoma: source of the MUC1-specific TCR 
 The source of the MUC1-specific TCR is an MHC-class II restricted, CD4+ T cell 
hybridoma, VF5, which was generated in our laboratory and described previously (165).  VF5 is 
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 specific for a 12aa peptide GVTSAPDTRPAP derived from the tandem repeat region of 
unglycosylated MUC1.  The VF hybridomas were generated by fusing the AKR thymoma 
BW5147 (167) with CD4+ T cells isolated from WT mice immunized with unglycosylated 
synthetic MUC1 100mer.  Hybridoma clone VF5 displayed the highest avidity for MUC1 
100mer, as tested by IL-2 production in response to 100mer-loaded DC.  The high-affinity 
MUC1-specific TCR expressed by VF5, hereafter called “VF5 TCR” or “VF5αβ”, is therefore 
representative of the TCRs that are expressed by peripheral MUC1-specific effector CD4+ T 
cells in WT mice.   
 
3.2.3. Expression of BW5147 TCR genes in the VF5 hybridoma 
Cloning of the MUC1-specific TCR was confounded by the presence of multiple TCR re-
arrangements in the VF5 hybridoma.  We found that the TCR loci of both fusion partners, the 
original MUC1-specific T cell and the BW5147 thymoma, carried several productive VDJ 
rearrangements, all of which are expressed in the VF5 hybridoma.  As will be described later in 
more detail, the MUC1-specific TCR was identified by the variable gene segments of its alpha 
and beta chains, Vα2.7 and Vβ6, respectively.  The BW5147-derived TCR contains Vα1.1 and 
Vβ1.1 (168). 
 
Adding a further level of complexity, the BW5147 fusion partner actually carries V(D)J 
rearrangements in all of its TCR loci (i.e. both TCRα loci and both TCRβ loci).  Of these 
rearrangements, only two are productive, resulting in protein expression of Vα1.1 and Vβ1.1.  
The two non-productive TCR re-arrangements, involving Vα16 and Vβ5.2, are expressed at the 
mRNA level only due to in-frame stop codons which prematurely terminate protein translation.  
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 The VF5 hybridoma, which was the result of fusing BW5147 with the MUC1-specific T cell, 
contains 4N chromosomes and carries all of the TCR rearrangements from the parent cells.  
Thus, the VF5 hybridoma expresses three TCRα chain mRNAs and three TCRβ chain mRNAs, 
(see table 2).  Of these TCR mRNA species, two TCR alpha chains (Vα1.1 and VF5α) and two 
beta chains (Vβ1.1 and VF5β) are translated into full-length protein and expressed at the cell 
surface.  Either of the TCRα chains can associate with either of the TCRβ chains, potentially 
resulting in the expression of four different heterodimeric TCRαβ combinations on the cell 
surface of VF5:  Vα1.1/Vβ1.1; Vα1.1/VF5β; VF5α/Vβ1.1 and VF5α/VF5β.  The latter 
combination was assumed to be the MUC1-specific TCR of interest, to be identified and cloned. 
 
Table 2.  TCR Re-arrangements in the VF5 hybridoma 
Original 
Source 
TCRα gene 
segments 
TCRβ gene 
segments 
Productive 
Rearrangement?
mRNA 
expression? 
Protein 
expression? 
MUC1-specific 
T cell Vα2.7-Jα49 Vβ6-Jβ2.5 Yes Yes Yes 
BW5147 Vα1.1 Vβ1.1 Yes Yes Yes 
BW5147 Vα16 Vβ5.2 No Yes No 
 
 
 
3.2.4. Designing Methods for identifying the VF5 TCR 
Cloning of the VF5 TCR was more complicated than simply performing PCR amplification of 
the TCR with 5’ and 3’ flanking primers, as this would indiscriminately amplify all of the TCR 
mRNA species.  Primers were needed that could specifically amplify the MUC1-specific TCR 
but not the fusion partner TCR.  In order to design such primers, it was first necessary to identify 
the variable and joining gene segments that are incorporated in the VF5 TCR. 
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Due to the paucity of Vα-specific antibodies, it was not possible to use flow cytometry to 
identify the VF5 TCR alpha chain.  Similarly, the commercially available Vβ antibody kits did 
not cover all of the known Vβ gene segments.  Therefore, a molecular approach was used to 
identify the V and J gene segments that are incorporated into the MUC1-specific TCR.  This 
methodology involved RT-PCR amplification of the unknown TCRα and β chains, followed by 
sequencing of the amplicon and alignment with a database of known murine TCR V/J gene 
sequences (169).   
 
The major challenge was to specifically amplify and clone the MUC1-specific TCR chains 
without actually knowing their sequence.  To this end, two slightly different RT-PCR-based 
techniques were used for identification of the unknown VF5α and VF5β chains.  They will be 
described in detail in the following section.  The VF5 TCRα chain was identified by 5’RACE.  
The VF5 TCRβ was identified using degenerate primers that bind to all the Vβ gene segments. 
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 1. Amplify V(D)J from mRNA by 5’ RACE or degenerate primers:
2. Clone the PCR product and check the DNA sequence to identify the V and J 
gene segments
3. Design appropriate primers to clone VDJ from genomic DNA:
4. Clone the genomic fragment into TOPO vector.
5. Sub-clone into expression vector (pTα/pTβ)  
Figure 3-2. Overview of the identification and cloning of the VF5 TCR 
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 3.3. Materials & Methods 
 
Unless otherwise specified, all PCR primers were synthesized in the DNA synthesis facility at 
the University of Pittsburgh.  All DNA sequencing was performed in the DNA sequencing 
facility at the University of Pittsburgh.  All mouse cells were cultured in complete DMEM 
(cDMEM) containing 10%FBS, Penicillin & Streptomycin, L-Glutamine, Na Pyruvate, Non-
Essential Amino Acids, Hepes Buffer, and β-2 Mercaptoethanol. 
 
 
 
3.3.1. TCRα 5’ RACE 
Total cellular RNA was isolated from the VF5 hybridoma using an RNeasy mini kit (Qiagen, 
CA).  5’ RACE was performed using a Generacer Kit (Invitrogen, CA).  Total cellular DNA was 
synthesized using the supplied oligo dT primers, as per the manufacturer’s instructions.  The 
TCRα chains were then amplified by nested PCR using forward primers specific to the ligated 5’ 
Oligo (supplied in the Generacer Kit): 5’ CGACTGGAGCACGAGGACACTGA 3’ and 5’ 
GGACACTGACATGGACTGAAGGAGTA 3’; paired with a reverse primer specific for the 
TCRα constant gene segment: 5’ ACAGCAGGTTCTGGGTTCTGG 3’.  After electrophoreses 
in a 1% agarose gel containing ethidium bromide, the RACE product was eluted using a 
GenElute gel extraction kit (Sigma, MO), then TA cloned into the pCR4-TOPO vector and 
transfected into chemically competent TOP10 E. coli using a TOPO-TA cloning Kit (Invitrogen, 
CA).  Transfected bacteria were grown on selection overnight in LB broth containing 100μg/mL 
ampicillin (Sigma, MO) and then cloned by spreading on a plate of LB agar containing 
100μg/mL ampicillin.  Individual colonies were screened by PCR for the presence of a TCRα 
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 RACE product using the Cα-specific primer (see above), coupled with T7 or T3 primers specific 
for the vector (supplied in the TOPO-TA kit).  TCRα+ clones were then screened by a second 
PCR to eliminate those clones that contained either of the fusion partner TCRα fragments, 
Vα1.1 (primer sequence, 5’ GCACTCTGGGAAAAGCCCC 3’) and Vα16 (primer sequence, 5’ 
GGAAGAACAGAAAGTTTTCACGCTCC 3’).  Recombinant plasmids containing the 
unknown VF5α chain were isolated from TCRα+ Vα1- Vα16- clones using a plasmid mini kit 
(Qiagen, CA) and were subsequently sequenced in the DNA sequencing facility at the University 
of Pittsburgh School of Medicine. 
 
3.3.2. Cloning the VF5α chain into pTα 
Genomic DNA was isolated from the VF5 hybridoma using a DNeasy kit (Qiagen, CA).  The 
VF5α VJ fragment was amplified by PCR primers specific for Vα2.7 
(5’CATCTCCCGGGATGGACAAGATCCTGACAGCGC 3’) and the downstream intron of 
Jα49 (5’ GCGGTGGCGGCCGCAATTAGGACAGAGCTTTAGC 3’), using Pfu turbo Hotstart 
DNA polymerase (Stratagene, CA).  These primers introduced flanking restriction enzyme sites 
for XmaI and NotI, respectively.  PCR was performed at 3mM MgCl2 for 30 cycles with an 
annealing temperature of 55oC.  The 769bp VF5 VJα genomic fragment was eluted from a 1% 
agarose gel using an EthBr Minus kit (Sigma, MO) and terminal overhanging adenine 
nucleotides added using Taq polymerase (Applied Biosystems, CA).  The VF5 VJα genomic 
fragment was TA-cloned into pcDNA3.1/V5-His (Invitrogen, CA) and propagated in TOP10 
E.coli (Invitrogen, CA) in LB media containing 100μg/ml ampicillin (Sigma, MO).  VF5α+ 
clones were identified by PCR using the vector-specific primers T7 and BGH (Invitrogen, CA), 
paired with a Jα49-specific primer (5’ CCTTCCCAAATGACAGCTTAGA 3’).  The integrity of 
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 the cloned sequence was confirmed by the DNA sequencing facility at the University of 
Pittsburgh.  pcDNA3.1-VF5α and pTα were digested with XmaI and SacII and the resulting 
fragments resolved by agarose gel electrophoresis.  The 825bp VF5α fragment and ~19kb pTα 
were eluted from the gel with Etr Minus columns (Sigma, MO) and ligated with T4 ligase (New 
England Biolabs, MA).  The ligation product was transfected into TOP10 E.coli (Invitrogen, CA) 
and transfectants selected in LB media containing 100μg/ml ampicillin.  Colonies were screened 
by PCR for pTα containing VF5α inserted in the correct orientation, using primers specific for 
Vβ2.7 (5’ CACAATCTTCTTCAATAAAAGGGAGAA 3’) and pTα (5’ 
TACACTGGCCAGTCACGGA 3’). 
 
 
3.3.3. RT-PCR with degenerate Vβ primers 
Total cellular RNA was isolated from the VF5 hybridoma using an RNeasy mini kit (Qiagen, 
CA) and cDNA synthesized with Oligo-dT using a GeneAmp RNA PCR kit (Applied 
Biosystems, CA), according to the manufacturer’s instructions.  PCR amplification of TCRβ 
cDNA was performed using a reverse primer specific for TCR Cβ (5’ AATCTCTGCT 
TTTGATGGCT 3’) and degenerate Vβ-specific primers, as previously published (170) at a 
[MgCl2] of 2mM.  The TCRβ cDNA fragment was eluted from a 1% agarose gel using a 
Genelute kit (Sigma, MO) and TA cloned into pCR4-TOPO (Invitrogen). pCR4-VF5β was 
transfected into Top10 E.coli, which were grown in LB plus 100μg/ml ampicillin and screened 
for the presence of Cβ using T7 and T3 primers (Invitrogen) paired with a Cβ-specific primer ( 
5’ GAGACCTTGG GTGGAGTCAC 3’).  Plasmids isolated from VF5β+ clones using a plasmid 
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 mini kit (Qiagen, CA) were sequenced by the DNA sequencing facility at the University of 
Pittsburgh. 
 
3.3.4. Cloning the VF5β chain into pTβ 
The VF5 VDJβ fragment was amplified from genomic DNA by PCR using the Pfu turbo 
Hotstart DNA polymerase (Stratagene, CA) and primers specific for Vβ6.1 ( 5’ 
CAGTATGTCGACATGAACAAGTGGGTTTTCTGCTGGGTAA 3’) and the downstream 
intron of Jβ2.5 (5’ ACAAACCCGCGGAACCCTGTGACTCCCAAGAGAAA 3’).  These 
primers introduced flanking restriction enzyme sites for SalI and SacII, respectively.  PCR was 
performed at 3mM MgCl2 for 35 cycles with an annealing temperature of 55oC.  The 631bp VF5 
VDJβ PCR product was eluted from a 1% agarose gel using an EthBr Minus kit (Sigma, MO) 
and terminal overhanging adenine nucleotides added using Taq polymerase (Applied 
Biosystems, CA).  The VF5 VDJβ genomic fragment was TA-cloned into pcDNA3.1/V5-His 
(Invitrogen, CA) and propagated in Stbl IV E.coli (Invitrogen, CA) at 30oC in LB media 
containing 100μg/ml ampicillin (Sigma, MO).  VF5β+ clones were identified by PCR using 
primers specific for Vβ6 (5’ TCAATAACTGAAAACGATCTT 3’) and Jβ2.5 (5’ 
TAACACGAGGAGCCGAGT 3’).  The integrity of the cloned sequence was confirmed by the 
DNA sequencing facility at the University of Pittsburgh.  The cloned VF5β genomic fragment 
was excised from pcDNA3.1 with SalI and SacII.  pTβ was digested with XmaI and SacII.  The 
resulting fragments were resolved by electrophoresis in a 1% agarose gel, eluted with Etr Minus 
columns (Sigma, MO) and ligated with T4 ligase (New England Biolabs, MA).  The pTβ-VF5β 
ligation product was transfected into TOP10 E.coli (Invitrogen, CA) and transfectants selected in 
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 LB media containing 100μg/ml ampicillin.  Colonies were screened by PCR for the presence of 
VF5β, using the same primers specific for Vβ6 and Jβ2.5 described above. 
 
Propagation of pTβ-VF5β in Stbl4 E.coli 3.3.5. 
3.3.6. 
Restriction analysis indicated that the pTβ-VF5β expression construct is unstable and susceptible 
to self-recombination events, leading to the accumulation of spurious recombinants of varying 
sizes.  To combat this, pTβ-VF5β was propagated in Stbl4 E.coli (Invitrogen, CA), which lack 
several DNA recombination enzymes and therefore maintain large and unstable plasmids more 
faithfully.   
 
ELISA on DO.11.10 transfectants 
1 x 106 DO.11.10 cells were co-transfected with 5μg of pTα-VF5α, 5μgpTβ-VF5β, and/or 0.5μg 
pEF6 (Invitrogen, CA), by electroporation at 280mV and 960μF.  Electroporated cells were 
rested overnight in cDMEM then grown for two weeks in cDMEM supplemented with 5μg/ml 
Blasticidin (Invitrogen, CA).  DO.11.10 cells transfected with pTα-VF5α were stained with anti-
Vα2 MAb (BD Biosciences, CA) and sorted on a FACSaria (BD Biosciences, CA).  Presence of 
pTβ-VF5β was confirmed by RT-PCR using the primers specific for Vβ6 and Jβ2.5 described 
above.  105 DO.11.10 cells were stimulated for 24 hours with 104 day6 BMDC loaded with 
50ug/mL MUC1 100mer.  Supernatants were harvested and analysed for presence of IL-2 using 
an IL-2 OptEIA ELISA set (BD-Pharmingen, CA), as per the manufacturer’s instructions. 
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 3.3.7. 
3.3.8. 
Generation of VFT Mice 
Founder VF5α and VF5β mice were generated in the transgenic mouse facility at the University 
of Pittsburgh School of Medicine by microinjection of C57BL/6 Thy1.1 embryos with the pTα-
VF5α and pTβ-VF5β constructs, respectively.  Injected embryos were implanted into 
pseudopregnant C57BL/6 Thy1.1 females.  VF5α and VF5β founder mice were identified by 
PCR of tail DNA using primers specific for the Vα2-Jα49 and Vβ6-Jβ2.5 rearrangements.  
Founders were bred with Thy1.1 mates to confirm that the transgenes were in the germline.  
Then VF5α and VF5β F1 progeny were cross-bred to produce double-transgenic VFT mice, 
carrying both VF5α and VF5β transgenes. 
 
Detection of VF5 TCR expression by flow cytometry 
Expression of the transgenic TCR chains on the surface of T cells was confirmed by flow 
cytometry.  Cells were stained with monoclonal antibodies specific for Va2 and Vβ6.  The PE-
conjugated Va2 MAb (clone B20.1, BD Biosciences, CA) was used at 1:50 dilution.  The Vβ6-
specific antibody was produced by the hybridoma clone 44-22-1, a generous gift from Dr Pamela 
Ohashi (University of Toronto), and was applied to cells in the form of raw hybridoma culture 
supernant.  The hybridoma was grown to confluence for up to 1 month in Iscove’s Modified 
Eagle Media (Cellgro, Mediatech, VA), containing 10%FBS, Penicillin & Streptomycin, L-
Glutamine, Na Pyruvate, Non-Essential Amino Acids, Hepes Buffer, and β-2 Mercaptoethanol.  
Supernatant was harvested and stored at 4oC in the dark and used, unpurified to stain cells for 
Vβ6.  FitC-conjugated anti-mouse IgG2a secondary antibody (BD Biosciences, CA) was then 
used to detect surface-bound 44-22-1 MAb.  Due to cross-reactivity of the secondary antibody 
69 
 with the Vα2 MAbs (Rat IgG2a isotype), the three antibodies were applied in succession in the 
following order: 44-22-1 supernatant…FitC-anti-mouse IgG2a…PE-anti-Va2. 
 
3.3.9. 
3.3.10. 
Generation of Bone Marrow DC 
BMDC were generated as described earlier in chapter 2.  Briefly, BM cells isolated from mouse 
femurs were cultured for 7days in cDMEM containing 10ng/ml each of GM-CSF and IL-4 (a 
generous gift from Immunex, WA) and fed every two days by adding 5ml cDMEM containing 
10ng/ml GM-CSF and IL-4.  On day 7 of culture, cells were harvested and purified by density 
centrifugation using Nycoprep 1.068 (Accurate Chemical, NY).   
 
 
Vaccinations and adoptive T cell transfers 
Purified day7 DC were loaded for 6 hours with 20-50ug/mL synthetic MUC1 100mer, washed 
twice with PBS and resuspended in PBS at 5x105 cells/mL.  Soluble 100mer was added at 
500μg/ml.  Mice were injected subcutaneously in the right flank with 200μl PBS containing 105 
loaded DC and 100μg soluble 100mer.   
 
T cell donor mice were immunized with 100mer-pulsed DC, as described above.  Two weeks 
after immunization, LN and spleen were removed from donor mice and single cell suspensions 
prepared as described above.  CD4+ T lymphocytes were positively selected by magnetic 
antibody cell sorting (MACS) using CD4 (L3T4) Microbeads (Miltenyi Biotech, CA).  Purified 
CD4+ T cells were washed and resuspended in sterile PBS.  Prior to injection of T cells, mice 
were placed under a heat lamp to induce vasodilation.  Then 1 x106 - 5 x106 CD4+ T cells in 
200μl PBS were injected into mice via the lateral tail vein using a 27½ gauge syringe.   
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3.4. Making the VFT mouse: Results 
 
3.4.1. Identification of the VF5 TCR VJα by 5’RACE 
The MUC1-specific VF5α chain was amplified by 5’RACE (Rapid Amplification of cDNA 
Ends) PCR.  This method is ideal for the amplification of a gene in which the sequence of the 3’ 
end is known, but the 5’ sequence is yet to be determined.  This exact situation exists in TCR 
chains of unknown identity; the Variable and Joining regions could be encoded by any of the 
available V and J gene segments, but the constant regions is, by definition, always encoded by 
the same gene segment.  In 5’ RACE, a short oligonucleotide was ligated to the 5’ end of cellular 
mRNA prior to its reverse transcription into cDNA.  As the reverse transcriptase proceeds from 
the 3’ poly-A tail, synthesizing a complementary strand to the mRNA encoding the TCRα, it 
continues through the oligonucleotide ligated to the 5’ end.  The resulting TCRα cDNA 
contained the unknown VDJ fragment, flanked by two known sequences (i.e. the 5’ ligated oligo, 
and the 3’ constant gene segment).  This was then amplified by PCR using primers specific for 
the 5’ oligo and the TCRα constant gene segment.  The Cα reverse primer ensured that only 
TCRα cDNA would be amplified.  However, as the Cα primer does not distinguish between the 
MUC1-specific TCRα or the fusion partner TCRα chains, all three TCRα species are amplified 
and represented as a single band upon electrophoresis in an agarose gel (fig 3-3).   
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 VF5a vs known Vα2.7 sequence…
Identity = 361/361 (100%)
… and vs known Jα49 sequence… Identity = 62/62 (100%)
>VF5a-5  length=449bp 
ATGGACAAGATCCTGACAGCAACGTTTTTACTCCTAGGCCTTCACCTAGCTGGGGTGAATGGCCAGCAGCAGGAGAA
ACGTGACCAGCAGCAGGTGAGACAAAGTCCCCAATCTCTGACAGTCTGGGAAGGAGAGACCGCAATTCTGAACTGCA
GTTATGAGGACAGCACTTTTAACTACTTCCCATGGTACCAGCAGTTCCCTGGGGAAGGCCCTGCACTCCTGATATCC
ATACGTTCAGTGTCCGATAAAAAGGAAGATGGACGATTCACAATCTTCTTCAATAAAAGGGAGAAAAAGCTCTCCTT
GCACATCACAGACTCTCAGCCTGGAGACTCAGCTACCTACTTCTGTGCAGCAACGAAGCAAGGCACTGGGTCTAAGC
TGTCATTTGGGAAGGGGGCAAAGCTCACAGTGAGTCCAGACATCCAGAACCCAGAACCTGCTGT 
 
AA = Va2.7 AA = Ja49    AA = Ca     
A
B
C
 
 
Figure 3-3. VF5 TCRa contains Vα2.7 and Jα49 
A) The 550bp VF5 TCR VJα was amplified by 5’RACE eluted from a 1% agarose gel and TOPO-cloned into 
pCR4-TOPO  B) Sequence of the TCRα RACE product matches known sequences of Vα2.7 and Jα49 in the 
BLAST database.  C) Expression of Va2 on the surface of VF5 was confirmed by FACS using anti-Vα2 MAb. 
 
 
 
The three species of TCRα chains amplified by 5’RACE therefore needed to be separated before 
VF5α could be accurately sequenced.  To do this, the 550bp TCRα RACE product was eluted 
from the agarose gel, and TOPO cloned into pCR4-TOPO.  Individual clones were screened by 
PCR for the unknown VF5α, as determined by the presence of a TCRα chain that was not Vα1.1 
or Vα16.  The VF5 VJα sequence from five clones was aligned with the BLAST database and 
also with published sequences of all the known murine TCR Vα genes (169) and Jα genes (171).  
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 These analyses revealed that the MUC1-specific TCRα contains Vα2.7 and Jα49 (fig 3-3).  Cell 
surface expression of Va2 was confirmed by FACS using a Va2-specific antibody (fig 3-3).  
Thus, the MUC1-specific TCRα chain was identified and found to contain the Vα2.7 and Jα49 
gene segments. 
 
 
 
MgCl2 MgCl2
DO.11.10 VF5
55oC Tm
2-4mM MgCl2
 
Figure 3-4. PCR amplification of VF5α 
VF5a TCR was amplified from genomic DNA using primers specific for the 5’ and of Vα2.7 and the 3’ Jα49 intron.  
DO.11.10 (shares the same fusion partner as VF5) was used as a negative control for specificity of PCR 
amplification. 
 
 
3.4.2. Cloning the VF5 TCRα  into the pTα cassette vector 
With the VF5α chain gene segments identified, it was possible to design primers specific for the 
Vα2.7-Jα49 rearrangement that could be used to specifically amplify the VF5 TCRα chain from 
genomic DNA (fig3-4):  The forward cloning primer was specific for the leader sequence of 
Va2.7; the reverse cloning primer was specific for the 3’ intron of Jα49.  A high fidelity DNA 
polymerase, Pfu turbo, was used to ensure faithful replication of the gene sequence.  The 
genomic TCRα fragment cloned from VF5 contained the complete variable domain of the 
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 MUC1-specific TCR, from the Vα2.7 leader sequence, to a point 150nt downstream of the Jα49 
gene segment.  We included part of the 3’ Jα49 intron, as this contains the splice donor site 
necessary for splicing of the VJ exons with the Cα exon in pTα.  The VF5α fragment was 
initially TA cloned into the pcDNA3.1/V5-His plasmid, to allow its sequence to be verified, and 
subsequently sub-cloned into the pTα expression vector by virtue of flanking Xma I and Sac II 
restriction sites, which were engineered into the TCRα fragment by the cloning primers.  Fig 3-5 
shows a map of the final expression construct. 
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SacII, SacI
3.0
20.1 Kb
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Figure 3-5. Map of the pTαVF5α expression construct 
The VJα fragment cloned from VF5 was inserted into the XmaI/NotI cloning site.  The VJα exon is spliced to the 
Cα exon during mRNA processing.  The pEMBL18 prokaryotic backbone is necessary for propagation in E.coli and 
provides the Neo gene for resistance to G418 (Genticin), to allow selection of transfectants.  This prokaryotic 
sequence was removed by digestion with SalI prior to injection into the mouse embryos. 
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3.4.3. Identification of VF5 TCRβ using degenerate Vβ-specific primers 
 
Unlike VF5α, attempts to use 5’ RACE to identify the VF5 TCRβ chain were unsuccessful; 
despite modification of various parameters, a TCRβ RACE product was never obtained.  
Therefore an alternative approach was taken involving RT-PCR amplification of the TCRβ 
chains using a Cβ-specific reverse primer in combination with degenerate forward primers which 
will anneal to all of the known Vβ gene segments (170).  Similar to 5’RACE, this method 
allowed amplification across the unknown VDJ region.  As for the VF5α chain, the RT-PCR 
product was eluted from an agarose gel and TA-cloned into pCR4-TOPO to separate the MUC1-
specific VFJβ from those derived from the BW5147 fusion partner.  BLAST alignment of 
sequences from several clones indicated that the MUC1-specific TCRβ chain contains Vβ6 and 
Jβ2.5 (fig 3-6).  Owing to the lack of a good Vβ6 MAb at this time, the presence of this 
rearrangement in VF5 was confirmed by PCR using primers specific for the Vβ6 CDR and Jβ2.5 
(fig 3-7). 
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 Reverse Primer:   Cβ1    Cβ2     Cβ3
>pCR4-VF5β3
CGAATGAATTTAGCGGCCGCGAATTCGCCCTTN CGTACCCAAAATCCT GATTGGTCAGGAAGG G
CAAAAACTGACCTTGAAATGTCAACAGAATTTCAATCATGATACAATGTACTGGTACCGACAG G
ATTCAGGGAAAGGATTGAGACTGATCTACTAT TCAATAACTGAAAACGATCTT CAAAAAGGCGA
TCTATCTGAAGGCTATGATGCGTCTCGAGAGAAGAAGTCATCTTTTTCTCTCACTGTGACATC T
GCCCAGAAGAACGAGATGGCCGTTTTTCTCTGTGCCAGCAGTAT ACTGGGGGGCC AAGACACCC
AGTACTTTGGGCCAGGCACTCGGCTCCTCGTGTTAG AGGATCTGAGAAAT GTGACTCCACCCA A
GGTCTCCTTGTTTGAGCCATCAAAAGCAGAGATTAAGGGCGAATTCGTTTAAACCTGCAGGAC T
AGTCCCTTTAGTGAGGGTTAATTCTGAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTG
NN = Vector Sequence
NN = Vβ gene segment
NN = Dβ gene segment
NN = Jβ gene segment
NN = Cβ gene segment
NN = Vβdeg primer site
 CβNIII primer site
VF5β matches Vβ6:
Identities = 263/264 (99%) Strand = Plus / Plus
NN =
…and Jβ2.5:
Identities = 100%
A
B
C
 
Figure 3-6. Identification of VF5β, containing Vβ6 and Jβ2.5 
A) Degenerate forward primers specific for the Vβ gene segments were used in combination with one of three 
different Cβ-specific reverse primers.  B) Sequence results from the “Cβ2” RT-PCR product.  C) The VF5β 
sequence matches Vβ6 and Jβ2.5. 
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Figure 3-7. Expression of Vβ6 in the VF5 hybridoma 
A) Anti-Vβ6 MAb (clone RR4-7) does not recognize the VF5 TCR:  Blue histogram, isotype control antibody; 
green histogram, RR4-7. 
B) The Vβ6Jβ2.5 mRNA rearrangement is only expressed in VF5:  RT-PCR amplification from total mRNA using 
primers specific for Vβ6 and Jβ2.5. 
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 3.4.4. Cloning the VF5 TCRβ  into the pTβ cassette vector 
Using this information, PCR primers specific for Vβ6 and the 3’ Jβ2.5 intron were designed to 
specifically amplify the genomic VF5 VDJβ fragment, including 150bp of downstream intron.  
The introduction of flanking restriction enzyme suitable for insertion of the VDJβ fragment into 
pTβ was more complicated than for the VF5α fragment.  The only restriction enzyme sites 
available in the pTβ cassette were the 5’ XhoI and 3’ SacII.  However, the presence of an XhoI 
site in the middle of the Vβ6 gene segment precluded the use of XhoI at the 5’ end of the VDJβ 
fragment.  Therefore, a SalI restriction site, which is compatible with XhoI, was engineered into 
the 5’ cloning primer.  The amplified cloned VDJβ fragment was cut with SalI and SacII, pTβ 
was cut with XhoI and SacII, and the VF5β fragment was ligated into the pTβ cassette.  Fig 3-8 
shows a map of the final expression construct. 
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Figure 3-8. Map of the pTβ-VF5β expression construct 
The VF5 VDJβ genomic fragment was cut with SalI and SacII and inserted into pTβ via the 5’XhoI and 3’ SacII 
cloning sites.  The cloned VDJβ exon is spliced to Cβ during mRNA processing to allow expression of full-length 
VF5 TCRβ. 
Restriction analysis of this final construct revealed an anomaly in the map of the pTβ cassette originally published 
(166).  This map includes the correct positions of restriction sites from 4.97kb SalI through 20.45kb KpnI. 
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 3.4.5. MUC1-specificity of the cloned VF5 TCRαβ 
 
Before proceeding to the generation of the VF5 TCR-Tg mouse, the integrity and MUC1-
specificity of the pTα-VF5α and pTβ-VF5β constructs was tested by transfecting them into the 
DO.11.10 hybridoma.  After confirming expression of the VF5 TCR chains in the DO.11.10 
transfectants (fig 3-9), their ability to produce IL-2 in response upon stimulation by MUC1-
presenting DC was tested by ELISA of culture supernatants. 
Concomitant expression of VF5 TCRα and TCRβ constructs conferred specificity for MUC1 
upon DO.11.10 (fig 3-9).  Control DO.11.10 cells transfected with either VF5α or VF5β 
individually did not respond to MUC1.  This proved that the cloned TCRα and β chains are 
derived from the MUC1-specific TCR in VF5 and that they are necessary and sufficient for 
MUC1-specificity.  As DO.11.10 shares the same fusion partner as VF5, the fact that either 
construct alone did not confer MUC1 specificity on DO.11.10 rejects the possibility that the 
MUC1-specific TCR in VF5 may have been contained one of the TCR chains derived from 
BW5147. 
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Figure 3-9. The cloned VF5 TCR is MUC1-specific 
The VF5 TCR expression constructs pTα-VF5α and pTβ-VF5β were co-transfected into DO.11.10 with pEF6 
(encoding the ble resistance gene) and grown in blasticidin selection for 1 week.  (A) Transfectants expressing 
VF5α were stained with a MAb specific for Va2 and sorted by FACS. (B) Due to the unavailability at this time of a 
Vβ6-specific MAb, VF5β expression was confirmed by RT-PCR using primers specific for Vβ6 and Jβ2.5.  The 
200bp band indicates expression of VF5β mRNA.  (C) Transfectants were stimulated with MUC1-pulsed DC for 24 
hours and IL-2 production was measured by ELISA of culture supernatants.  The original VF5 hybridoma was 
included in the stimulation assay as a positive control.  (B and C), x-axis labels indicate constructs that were 
transfected into the cells. 
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 3.4.6. The VFT TCR-Tg mouse 
 
The pTα-VF5α and pTβ-VF5β TCR expression constructs were used to create the TCR 
transgenic mouse, “VFT”, whose CD4+ T cells are specific for MHC Class II restricted MUC1 
100mer.  Single transgenic VF5α and VF5β founder mice were generated separately on a 
C57BL/6 Thy1.1 congenic background.  Presence of the transgenes in founder mice was 
confirmed by PCR amplification from tail DNA (fig 3-10).  Passage of the TCRα and β 
transgenes through the germline was confirmed in F1 progeny by breeding the founders with 
Th1.1 mates.  Correct expression of the transgenic receptors in T cells was confirmed by FACS 
(fig 3-10).  The VF5α and VF5β transgenic mice were then cross-bred to produce the double- 
transgenic mouse, VFT, in which 100% of CD4+ T cells (hereafter called “VFT cells”) express 
the MUC1-specific TCRαβ. 
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Figure 3-10. Expression of the transgenic TCR in VFT mice 
A) Detection of VF5α transgene in tail DNA by PCR.  Lane 1, VFTα mouse.  Lane 2, WT mouse 
B) Detection of VF5β transgene in tail DNA by PCR.  Lane 1, WT mouse.  Lane 2, VFTβ mouse 
C) VFT cells were stained with PE-conjugated anti-Va2 MAb 
D) VFT cells stained with 44-22-1 hybridoma supernatant, then FitC-conjugated anti-RatIgG2a 
 
The C57BL/6 Thy1.1 congenic background of the VFT mouse allows the VFT cells to be distinguished from host T 
cells when adoptively transferred into WT and MUC1-Tg mice, which express the Thy1.2 allele on their T cells. 
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 3.5. CD4+ T cells from VFT mice control MUC1-specific immune responses 
 
The VFT TCR-Tg mouse provides the perfect opportunity to study the fate of MUC1-specific 
CD4+ T cells after encountering their cognate antigen, and their subsequent effect on the overall 
immune response to MUC1.  Given the dual role of CD4+ T cells in enhancing and suppressing 
immune responses to MUC1 described in chapter 2, our initial experiments using this novel 
TCR-Tg mouse were set out to answer two main questions: 
 
1. How do VFT mice respond to the MUC1-DC vaccine, which induces both effector and 
suppressor CD4+ T cells in WT mice, but predominantly Tregs in MUC1-Tg mice? 
 
2. Does provision of MUC1-specific Th cells (now derived from VFT mice) enhance the 
immune response of MUC1-Tg mice to the DC vaccine. (i.e. does MUC1-specific help, actually 
help?). 
 
 
 
Immune Response of VFT mouse CD4+ T cells to MUC1-loaded DC. 3.5.1. 
 
The studies described in chapter 2 indicated that immunization of WT mice with MUC1-pulsed 
DC resulted in the expansion of FoxP3+ regulatory T cells.  To confirm conclusively that the 
responding Tregs are indeed MUC1-specific, VFT mice were vaccinated with MUC1-loaded DC 
and then tested for the presence of Tregs.  Compared with naïve littermates, increased numbers 
of FoxP3+ Tregs were observed in vaccinated VFT mice (Fig3-11a), confirming the results 
obtained previously in WT mice (figs 2-5, 2-7) that DC immunization induces Tregs. 
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 Interestingly, the expansion of Tregs by MUC1-pulsed DC is even more pronounced in VFT 
mice than in WT mice.  This is likely due to the fact that a very small proportion of CD4+ T cells 
in WT mice are MUC1-specific, compared with 100% in VFT mice.  In support of this 
conclusion, gating on Vα2+Vβ6+ ‘MUC1-specific’ T cells indicated that the proportion of 
MUC1-specific CD4+ T cells that are FoxP3+ Tregs is the same in WT mice and VFT mice 
(Fig3-11b).  The fact that FoxP3+ cells represented a lower proportion of Va2+Vb6+ cells than 
CD3+CD4+ cells can be explained by the fact that the Va2+Vb6+ gate includes both CD4 and 
CD8 T cells (the latter are not expected to be FoxP3+ Tregs). 
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Figure 3-11. MUC1-loaded DC induce Tregs in VFT mice  
WT and VFT mice were immunized sub-cutaneously with MUC1-loaded DC. The “Naïve” VFT mouse was injected 
with PBS.  Two weeks after vaccination, inguinal LN were analysed by FACS for presence of FoxP3+ cells. 
A) Proportion of FoxP3+ LN cells expressed as a percentage of total CD3+CD4+ T cells in the iLN. 
B) Percentage of Vα2+Vβ6+ cells expressing FoxP3. 
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 Adoptive immunotherapy with MUC1-specific CD4+ VFT cells 3.5.2. 
Results in chapter 2 describe that, in our attempts to adoptively provide MUC1-specific Th cells 
for MUC1-Tg mice, immunization of WT donor mice expanded MUC1-specific Tregs, which 
suppressed immune responses upon transfer into MUC1-Tg mice.  As all VFT cells are MUC1-
specific, it is not necessary to immunize VFT mice to expand the number of MUC1-specific T 
cells prior to adoptive transfer.  Given the increased number of MUC1-specific T cells in VFT 
mice, we reasoned that if naïve VFT cells are adoptively transferred into MUC1-Tg recipients, 
sufficient numbers should survive and become stimulated upon subsequent immunization to 
provide antigen-specific T cell help.  Our hypothesis was that provision of MUC1-specific T cell 
help in this manner should improve MUC1-specific immune responses in MUC1-Tg mice.  The 
results shown in fig 3-12 indicate that this was indeed the case, confirming our original 
hypothesis that adoptive transfer of MUC1-specific CD4+ T cells into MUC1-Tg mice restores 
the MUC1-specific immune response to its full potential.  This conclusion comes with the 
stipulation that Tregs must not be present among the transferred CD4+ T cells.  Otherwise they 
will dominate the Th cells and suppress the immune response to MUC1.  Importantly, this 
experiment proves that naïve MUC1-specific CD4+ T cells can function in the MUC1-Tg mouse, 
at least in the short-term. 
 
Also, MUC1-Tg recipients of primed VFT cells exhibited marginally reduced immune responses 
to subsequent vaccination with MUC1-loaded DC.  This is in keeping with our previous results 
from WT donor mice, and supports the claim that the FoxP3+ CD4+ T cells expanded by 
immunization of VFT mice (fig 3-11) are functional Tregs. 
86 
 0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
IF
N
-g
 p
ro
du
ct
io
n 
in
 D
LN
 (O
D
, 4
50
nm
)
None PrimedNaive
 
Figure 3-12. Naive VFT cells improve MUC1-specific immunity in MUC1-Tg mice 
MUC1-Tg mice were given naïve or primed VFT cells, or no T cells, and then immunized with MUC1-loaded DC.  
10 days post immunization, LN were harvested, stimulated in vitro with MUC1-loaded DC, then restimulated on 
day7.  After 24 hours of stimulation, culture supernatants were harvested and tested by ELISA for presence of IFNγ. 
X-axis labels indicate the cells that were adoptively transferred. 
 
 
 
3.6. Discussion 
 
This chapter describes the generation and characterization of a novel TCR-Tg mouse, VFT, 
whose CD4+ T cells express an MHC-class II restricted, MUC1-specific TCR.  MUC1-specific T 
cells in VFT mice respond to stimulation with MUC1-loaded DC in a similar fashion to T cells 
from WT mice.  VFT mice are therefore a useful tool for studying the behavior MUC1-specific 
CD4+ T cells in a variety of settings.  The first set of experiments performed with these new mice 
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 were designed to confirm our observations from WT and MUC1-Tg mice (described in chapter 
2), but in this case with a pure, MUC1-specific T cell population. 
 
3.6.1. 
3.6.2. 
VFT cells expressing a WT TCR are effectively activated by MUC1 
The OVA-specific TCR expressed endogenously by DO.11.10 hybridoma has a very low affinity 
for its cognate antigen.  When DO.11.10 is stimulated by DC presenting OVA, IL-2 is produced 
in such low quantities that it can only be detected using IL-2 dependent cell lines (172).  
However, when DO.11.10 cells were transfected with the VF5 TCRαβ, they responded to 
MUC1-loaded DC with over 200pg/ml IL-2, which was easily detected by ELISA (fig 3-9).  As 
the rest of the TCR signaling pathway in the hybridomas was the same, this result suggests that 
the MUC1-specific TCR cloned from VF5 has a high affinity for I-Ab-restricted MUC1, which is 
in keeping with the fact that the VF5 TCR was cloned from a WT effector T cell.  As MUC1 is 
not expressed in WT or VFT mice, their T cells develop in the absence of any central or 
peripheral regulation, which most often results in deletion of the high affinity TCRs.   
 
 
VFT CD4+ T cells enhance MUC1-specific immune responses in MUC1-Tg mice 
As all of the CD4+ T cells in VFT mice are MUC1-specific, it is not necessary to immunize the 
donor VFT mice to expand the numbers of MUC1-specific T cells, so the problem of Treg 
induction is circumvented.  We were therefore able to transfer naïve VFT cells into MUC1-Tg 
mice, knowing that all of the transferred cells are MUC1-specific, to determine their effect on 
MUC1-specific immune responses.  Restoration of the MUC1-specific Th response in MUC1-Tg 
in this manner appears to provide the support needed for establishment of effective MUC1-
88 
 specific immunity.  However, this experiment will need to be repeated with a larger number of 
mice.  If confirmed, this result has important implications for the design of anti-cancer vaccines, 
as it is now clear that in addition to stimulating CTL, such vaccines must also contain a 
component for the stimulation of tumor-specific Th responses. 
 
Naïve VFT CD4+ T cells can be primed in MUC1-Tg mice 3.6.3. 
Naïve MUC1-specific T cells that have not differentiated into either Th or Tregs should be 
susceptible to any peripheral tolerance mechanisms that might exist in the MUC1-Tg mouse.  
The fact that naïve VFT cells can be primed in MUC1-Tg mice and function as effective Th cells 
indicates that, whatever tolerance mechanisms exist in MUC1-Tg mice, they do not appear to 
affect the activation of naïve CD4+ T cells in the periphery, at least in the short term.  This 
provides hope for a possible immunological treatment for MUC1+ cancers.  Assuming that 
MUC1-specific T cells are present (or provided exogenously), they can be stimulated to provide 
effective MUC1-specific immunity.  This result also indicates that peripheral tolerance 
mechanisms that may exist in the MUC1-Tg mouse require some time to take effect.  With this 
in mind, it would be prudent to administer MUC1-specific vaccines to young individuals, as this 
would increase the chances that naïve MUC1-specific CD4+ T cells would be primed before they 
have been tolerized to self-MUC1.  We are currently engaged in additional experiments using 
VFT and MUC1-Tg mice to test this hypothesis. 
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 4.  Conclusions and Implications 
 
 
We have shown that the balance between CD4+ T cell help and regulation is critical for 
establishing effective immune responses to MUC1+ tumors.  In MUC1-Tg mice, MUC1-specific 
Th cells are not functional, so MUC1-specific Tregs that respond to MUC-DC vaccine are un-
opposed.  This results in suppression of MUC1-specific immune responses.  In spite of this 
immunosuppression, naïve MUC1-specific CD4+ T cells can be primed in MUC1-Tg mice to 
provide adequate help for the establishment of robust MUC1-specific CD8 T cell responses.  The 
challenge now is to design the most effective approach of generating the MUC1-specific T cell 
help that is a pre-requisite for effective anti-tumor immunity. 
 
4.1. Implications for adoptive immunotherapy of cancers 
The Th-Treg balance is critical in the setting of adoptive immunotherapy.  The data presented 
here are in agreement with other studies (71) which indicate that adoptive immunotherapy for 
MUC1+ tumors involves more than simply transferring a heterogeneous mix of T cells into the 
patient.  In order to dictate the desirable immune responses, the transferred T cells must be of a 
well-defined specificity and phenotype (i.e. Th cells, not Tregs).   
 
We showed that adoptive transfer of MUC1-primed CD4+ T cells results in selection of the Tregs 
over Th cells, presumably because Tregs are less susceptible to apoptosis than primed effector T 
cells (164).  So CD4+ T cells depleted of Tregs must be used instead.  Assuming that 
observations from the MUC1-Tg mouse translate into humans, the risk of the MUC1-specific Th 
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 cells causing autoimmunity is minimal because MUC1-specific Tregs are functional and will 
keep them in check. 
 
Interestingly, whereas primed CD4+ T cells suppressed MUC1-specific immune responses, naïve 
MUC1-specific CD4+ T cells improved the immune response in MUC1-Tg mice.  This suggests 
that naïve CD4+ T cells, like Tregs, may be less susceptible to apoptosis than primed Th cells.  In 
this case, it would be worth exploring alternative methods, such as TCR gene therapy, for 
increasing the frequency of MUC1-specific TCRs in the transferred population of naïve T cells.  
Studies are already underway in our laboratory and others to investigate better methods of 
delivering and expressing TCR genes to naïve T cells and T cell precursors (173-176). 
 
4.2. DC-induced Tregs: Implications for design of anti-cancer vaccines 
CD4+CD25+ Tregs were originally considered to be anergic, but recent studies, including those 
described here, indicate that their proliferation can be induced under certain circumstances 
(177,178).  The experiments described here implicate DC in the conversion of naïve MUC1-
specific T cells into CD4+CD25+ Tregs.  A similar phenomenon has been reported in other 
systems (60,74,159,179). The outcome of the DC:T cell interaction is affected by the 
maturation/activation status of the DC and the milieu of costimulatory molecules it provides to 
the T cell (35,159,180,181).  Originally only immature DC were implicated in the development 
of Tregs.  However, it is now clear that mature DC and semi-mature DC also possess this 
tolerogenic capacity (182).  Given the heterogeneous phenotype of the DC used to vaccinate the 
VFT mice (fig2-3), it is likely that the DC which converted naïve VFT cells into Tregs were a 
distinct sub-population from those DC which induced Th cells.  If it is possible to tease apart the 
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 maturation requirements for the different subsets of DC that induce Tregs and Th cells, this will 
aid the design of cancer-specific vaccines that favor the generation of Th responses over Tregs. 
 
 
4.3. What happens to MUC1-specific T cells during development? 
 
The generation of the VFT mouse in combination with the MUC1-Tg mouse provides a unique 
opportunity to study the development and behavior of MUC1-specific CD4+ T cells in a setting 
where MUC1 is expressed endogenously as a self-antigen.  The cause of the Th:Treg imbalance 
in the  MUC1-Tg mouse is still unknown.  Are high affinity MUC1-specific Th cells deleted in 
the thymus, while high affinity Tregs are allowed to survive and populate the peripehery?  Or do 
they survive negative selection, only to be subjected to peripheral tolerance mechanisms?  From 
the final experiment described here, one thing seems certain: Naïve MUC1-specific CD4 cells 
that have developed in the absence of MUC1 can function when MUC1 is expressed 
peripherally.  This is evidenced by the fact that we were able to effectively prime naïve MUC1-
specific CD4+ VFT cells in the MUC1-Tg mouse.  This provides conclusive evidence in support 
of a role for MUC1-specific CD4+ T cells in enhancing the immune response to MUC1.  All that 
remains is to find the most efficient way of generating those MUC1-specific Th cells in vivo.  If 
this can be achieved, the possibility of a cancer vaccine capable of stimulating effective, MUC1-
specific anti-tumor immune responses will become a reality. 
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 APPENDIX A 
 
 
 
Restriction enzyme analysis of pTβ-VF5β 
 
The pTβ-VF5β TCR expression construct was made by inserting the cloned VF5 TCRβ 
fragment into the pTβ expression construct.  This is described in detail in chapter 3.  The 
integrity of the expression construct was tested by restriction enzyme analysis.  When pTβ-VF5β 
was digested with KpnI, the resulting DNA fragments did not match the sizes that were predicted 
from the map of pTβ originally published by Kouskoff et al (166).  According to this published 
map (and allowing for the insertion of my cloned TCRβ), digestion of pTb-VF5b with KpnI was 
expected to produce three bands of sizes 2.9kb, 4.75kb and 12.77kb.  However, the observed 
fragments were 2.9kb, 5.2kb and 12.77kb (see figure below).  This unexpected result was 
obtained repeatedly, using several pTb-VF5b clones. 
 
L     1     6     7    10
2kb
5kb
10kb
 
Figure 4-1 Restriction Enzyme Analysis of pTβ-VF5β 
The pTβ-VF5β expression construct was propagated and cloned in Stbl4 E.coli.  Plasmids were purified from 
several clones and digested with KpnI for 4hours.  Resulting DNA fragments were resolved by electrophoresis in a 
1% agarose gel containing ethidium bromide.  Numbers indicate the Stbl4 clone from which the plasmids were 
purified.  L,1kb DNA ladder.  Digestion of clones 7 and 10 produced the correct size bands, as predicted by in silico 
analysis of the contig assembly sequence.  pTβ-VF5β#10 was eventually used to generate the VF5β transgenic 
mouse.  The ~6.1kb fragment in clones 1 and 6 is may have resulted from insertion of VF5β without removal of the 
original TCRβ from pTβ. 
 
 
To resolve this discrepancy, I determined the predicted sequence of pTb-VF5b and located the 
exact restriction enzyme sites listed on the published map of pTβ.  To do this, I referred to the 
description of pTβ in the Kouskoff manuscript, which lists the fragments of genomic DNA that 
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 were assembled to produce the pTb expression cassette.  Following this description, I obtained 
the sequences of those genomic fragments from the NCBI database, and made a contiguous 
sequence assembly  of the pTb-VF5b expression construct, which included the sequence of my 
inserted TCR VF5b fragment.  Then I identified the positions of the Kpn1 restriction sites within 
that construct.  Using this in silico method, KpnI restiction enzyme sites were identified at 
positions 0(20.45kb), 5.35kb and 17.52kb.  Complete digestion at these sites would produce 
bands of sizes 5.25kb, 12.17kb and 2.93kb.  These predicted band sizes are in corroboration with 
the bands that I observed after KpnI digestion of the pTb-VF5b expression construct cassette.  
The published map therefore contains an error, such that the fragment upstream of the cloned 
VDJ fragment is actually 500bp larger than published.  Figure 3-8 shows a predicted map of the 
pTb-VF5b expression construct used to make the VFTb mouse.  This map includes the updated 
restriction enzyme sites allowing for the 500bp correction. 
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